Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-[3-(2,5-dioxo-1-phenylimidazolidin-4-yl)propyl]guanidine + H2O
N-[3-(2,5-dioxo-1-phenylimidazolidin-4-yl)propyl]urea + NH3
-
-
-
?
1-[3-(2,5-dioxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-3-yl)propyl]guanidine + H2O
N-[[6-(benzyloxy)-1H-indol-2-yl]methyl]urea + NH3
-
-
-
?
1-[3-(2,5-dioxoimidazolidin-4-yl)propyl]guanidine + H2O
N-[3-(2,5-dioxoimidazolidin-4-yl)propyl]urea + NH3
-
-
-
?
1-[3-[1-(biphenyl-3-ylmethyl)-2,5-dioxoimidazolidin-4-yl]propyl]guanidine + H2O
N-(3-[1-[([1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)urea + NH3
-
-
-
?
1-[[6-(benzyloxy)-1H-indol-2-yl]methyl]guanidine + H2O
N-[[6-(benzyloxy)-1H-indol-2-yl]methyl]urea + NH3
-
-
-
?
4-carbamimidamido-N-(diphenylmethyl)butanamide + H2O
4-(carbamoylamino)-N-(diphenylmethyl)butanamide + NH3
-
-
-
?
4-[4-(3-carbamimidamidopropyl)-2,5-dioxoimidazolidin-1-yl]-2-ethoxy-N-(4-methoxyphenyl)benzamide + H2O
4-[4-[3-(carbamoylamino)propyl]-2,5-dioxoimidazolidin-1-yl]-2-ethoxy-N-(4-methoxyphenyl)benzamide + NH3
-
-
-
?
4-[4-(3-carbamimidamidopropyl)-2,5-dioxoimidazolidin-1-yl]-N-(4-methoxyphenyl)benzamide + H2O
4-[4-[3-(carbamoylamino)propyl]-2,5-dioxoimidazolidin-1-yl]-N-(4-methoxyphenyl)benzamide + NH3
-
-
-
?
4-[4-(3-carbamimidamidopropyl)-2,5-dioxoimidazolidin-1-yl]-N-phenylbenzamide + H2O
4-[4-[3-(carbamoylamino)propyl]-2,5-dioxoimidazolidin-1-yl]-N-phenylbenzamide + NH3
-
-
-
?
4-[4-[3-(carbamoylamino)propyl]-2,5-dioxoimidazolidin-1-yl]-N-(4-methoxyphenyl)benzamide + H2O
4-[4-[3-(carbamoylamino)propyl]-2,5-dioxoimidazolidin-1-yl]-2-methoxy-N-(4-methoxyphenyl)benzamide + NH3
-
-
-
?
acetyl-L-Arg methyl ester + H2O
acetyl-L-citrulline methyl ester + NH3
peptidylarginine deiminase 3
-
-
?
benzoyl-L-Arg + H2O
benzoyl-L-citrulline + NH3
peptidylarginine deiminase 3
-
-
?
benzoyl-L-Arg ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
peptidylarginine deiminase 3
-
-
?
filaggrin L-Arg + H2O
filaggrin citrulline + NH3
-
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
keratin L-arginine + H2O
keratin L-citrulline + NH3
peptidylarginine deiminase 3
-
-
?
N-(3-[1-[(2'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)guanidine + H2O
N-(3-[1-[(2'-chloro-3'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)urea + NH3
-
-
-
?
N-(3-[1-[(2'-chloro[1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)guanidine + H2O
N-(3-[1-[(2'-chloro[1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)urea + NH3
-
-
-
?
N-(3-[1-[([1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)urea + H2O
N-(3-[1-[(3'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,5-dioxoimidazolidin-4-yl]propyl)urea + NH3
-
-
-
?
N-(biphenyl-3-ylmethyl)-4-carbamimidamidobutanamide + H2O
N-[([1,1''-biphenyl]-3-yl)methyl]-4-(carbamoylamino)butanamide + NH3
-
-
-
?
N-[(1R)-1-(biphenyl-3-yl)ethyl]-4-carbamimidamidobutanamide + H2O
N-[(1R)-1-([1,1''-biphenyl]-3-yl)ethyl]-4-(carbamoylamino)butanamide + NH3
-
-
-
?
N-[(1S)-1-(biphenyl-3-yl)ethyl]-4-carbamimidamidobutanamide + H2O
N-[(1S)-1-([1,1''-biphenyl]-3-yl)ethyl]-4-(carbamoylamino)butanamide + NH3
-
-
-
?
N-[(3'-bromobiphenyl-3-yl)methyl]-4-carbamimidamidobutanamide + H2O
N-[(3''-bromo[1,1''-biphenyl]-3-yl)methyl]-4-(carbamoylamino)butanamide + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
S100A3-L-arginine + H2O
S100A3-L-citrulline + NH3
-
-
-
?
trichohyalin-L-arginine + H2O
trichohyalin-L-citrulline + NH3
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + H2O
2-acetyl-Gly-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + NH3
-
-
-
-
?
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + H2O
3-acetyl-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + NH3
-
-
-
-
?
Ac-Ala-Gly-Arg-Gly-Lys + H2O
Ac-Ala-Gly-Cit-Gly-Lys + NH3
-
-
-
-
?
Ac-Ser-Ala-Arg-Gly-Lys + H2O
Ac-Ser-Ala-Cit-Gly-Lys + NH3
-
-
-
-
?
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Ala-Lys + H2O
Ac-Ser-Gly-Cit-Ala-Lys + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys-Arg-His-Arg-acetyl-Lys-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Ala + H2O
Ac-Ser-Gly-Cit-Gly-Ala + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys + H2O
Ac-Ser-Gly-Cit-Gly-Lys + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly + H2O
Ac-Ser-Gly-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala + H2O
Ac-Ser-Gly-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + H2O
Ac-Ser-Gly-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys + NH3
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val + H2O
?
-
-
-
-
?
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val + H2O
Ac-Ser-Gly-Cit-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val + NH3
-
-
-
-
?
acetyl-L-Arg + H2O
acetyl-L-citrulline + NH3
peptidylarginine deiminase 1
-
-
?
acetyl-L-Arg methyl ester + H2O
acetyl-L-citrulline methyl ester + NH3
benzoyl-Arg + H2O
benzoyl-citrulline + NH3
-
-
-
?
benzoyl-Arg-ethyl ester + H2O
benzoyl-citrulline-ethyl ester + NH3
benzoyl-Arg-methyl ester + H2O
benzoyl-citrulline-methyl ester + NH3
benzoyl-Arg-NH2 + H2O
benzoyl-citrulline-NH2 + NH3
benzoyl-L-Arg + H2O
benzoyl-L-citrulline + NH3
benzoyl-L-Arg ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
benzoyl-L-arginine + H2O
benzoyl-L-citrulline + NH3
-
-
-
?
benzoyl-L-arginine amide + H2O
?
-
best small-molecule substrate for PAD4
-
-
?
benzoyl-L-arginine amide + H2O
benzoyl-L-citrulline amide + NH3
-
-
-
?
benzoyl-L-arginine ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
-
-
-
?
benzoyl-L-arginine methyl ester + H2O
benzoyl-L-citrulline methyl ester + NH3
-
-
-
?
beta-actin L-arginine + H2O
beta-actin L-citrulline + NH3
substrate for isoform PAD2 only
-
-
?
citrullinated histone H3 L-arginine + H2O
?
substrate for isoform PAD4 only
-
-
?
CXC chemokine ligand 10 L-Arg + H2O
CXC chemokine ligand 10 citrulline + NH3
-
-
-
-
?
CXC chemokine ligand 11 L-arginine + H2O
CXC chemokine ligand 11 L-citrulline + NH3
-
-
-
-
?
CXCL17 L-Arg + H2O
CXCL17 L-citrulline + NH3
-
-
-
?
CXCL26 L-Arg + H2O
CXCL26 L-citrulline + NH3
-
-
-
?
CXCL5 L-Arg + H2O
CXCL5 L-citrulline + NH3
-
-
-
?
CXCL8 L-Arg + H2O
CXCL8 L-citrulline + NH3
citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation
-
-
?
DDYSSSRDGYGGS + H2O
?
substrate for isoform PAD4
-
-
?
DGYGGSRDSYSSS + H2O
?
substrate for isoform PAD4
-
-
?
DSEGTWRKGPEAD + H2O
?
substrate for isoform PAD2
-
-
?
DSHKFDRDFIYSD + H2O
DSHKFDCitDFIYSD + NH3
DSHKHSREWLWSD + H2O
DSHKHSCitEWLWSD + NH3
DSHKWHRDFFYSD + H2O
DSHKWHCitDFFYSD + NH3
DSKFAFRGGIASD + H2O
DSKFAFCitGGIASD + NH3
DSKFHFRYAVASD + H2O
DSKFHFCitYAVASD + NH3
DSKFKFRYAYASD + H2O
DSKFKFCitYAYASD + NH3
DSKHFHRDFIYSD + H2O
DSKHFHCitDFIYSD + NH3
DSKHKSRDFVYSD + H2O
DSKHKSCitDFVYSD + NH3
DSKHLSREWMWSD + H2O
DSKHLSCitEWMWSD + NH3
DSKKFDRDHLYSD + H2O
DSKKFDCitDHLYSD + NH3
DSKKFDRGHLYSD + H2O
DSKKFDCitGHLYSD + NH3
DSKKFHRDFLYSD + H2O
DSKKFHCitDFLYSD + NH3
DSKKFHRGFLYSD + H2O
DSKKFHCitGFLYSD + NH3
DSKKFKRDFLFSD + H2O
DSKKFKCitDFLFSD + NH3
DSKKHDRDHLWSD + H2O
DSKKHDCitDHLWSD + NH3
DSKKHFRDKLYSD + H2O
DSKKHFCitDKLYSD + NH3
DSKKHFRGKLYSD + H2O
DSKKHFCitGKLYSD + NH3
DSKKKHREWVWSD + H2O
DSKKKHCitEWVWSD + NH3
DSKKLHRDHMESD + H2O
DSKKLHCitDHMESD + NH3
DSKKYDRDFLWSD + H2O
DSKKYDCitDFLWSD + NH3
DSKKYDRGFLWSD + H2O
DSKKYDCitGFLWSD + NH3
DSKWHHRDHLYSD + H2O
DSKWHHCitDHLYSD + NH3
DSKWHHRGHLYSD + H2O
DSKWHHCitGHLYSD + NH3
DSKWYHRNKFWSD + H2O
DSKWYHCitNKFWSD + NH3
DSQFAFRGASASD + H2O
DSQFAFCitGASASD + NH3
DSQWAFRHALFSD + H2O
DSQWAFCitHALFSD + NH3
DSRFYWRGGGKSD + H2O
?
substrate for isoform PAD2
-
-
?
DSSEELRGGGKSD + H2O
?
substrate for isoform PAD2
-
-
?
DSYRSWRDGYYSD + H2O
?
substrate for isoform PAD4
-
-
?
FFDSHKFDRDFIYSD + H2O
FFDSHKFDCitDFIYSD + NH3
FFDSHKHSREWLWSD + H2O
FFDSHKHSCitEWLWSD + NH3
FFDSHKKSREYVFSD + H2O
FFDSHKKSCitEYVFSD + NH3
FFDSHKLHREWMWSD + H2O
FFDSHKLHCitEWMWSD + NH3
FFDSHKWHRDFFYSD + H2O
FFDSHKWHCitDFFYSD + NH3
FFDSKHFDREWIWSD + H2O
FFDSKHFDCitEWIWSD + NH3
FFDSKHKSRDFVYSD + H2O
FFDSKHKSCitDFVYSD + NH3
FFDSKHLSREWMWSD + H2O
FFDSKHLSCitEWMWSD + NH3
FFDSKKFSRDHIESD + H2O
FFDSKKFSCitDHIESD + NH3
FFDSKKKHREWVWSD + H2O
FFDSKKKHCitEWVWSD + NH3
FFDSKKWSREYFFSD + H2O
FFDSKKWSCitEYFFSD + NH3
fibrin L-arginine + H2O
fibrin L-citrulline + NH3
fibrinogen + H2O
fibrinogen with citrullinated L-arginine residues
-
-
-
-
?
fibrinogen-L-arginine + H2O
fibrinogen-L-citrulline + NH3
filaggrin L-Arg + H2O
filaggrin citrulline + NH3
-
-
-
?
filaggrin L-Arg + H2O
filaggrin L-citrulline + NH3
-
-
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
filaggrin-L-arginine + H2O
filaggrin-L-citrulline + NH3
gamma-actin L-arginine + H2O
gamma-actin L-citrulline + NH3
substrate for isoform PAD2 only
-
-
?
glial fibrillary acidic protein L-arginine + H2O
glial fibrillary acidic protein L-citrulline + NH3
-
-
-
?
glial fibrillary acidic protein-L-arginine + H2O
glial fibrillary acidic protein-L-citrulline + NH3
GYGGGSRDGSYGG + H2O
?
substrate for isoform PAD4
-
-
?
histone H2A L-arginine + H2O
histone H2A L-citrulline + NH3
-
deimination occurs at Arg3 of the N-terminal sequence acetyl-SGRGK
-
-
?
histone H2A-L-arginine + H2O
histone H2A-L-citrulline + NH3
histone H3 L-arginine + H2O
histone H3 L-citrulline + NH3
-
-
-
-
?
histone H3-L-Arg + H2O
histone H3-L-citrulline
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
histone H4 L-arginine + H2O
histone H4 L-citrulline + NH3
-
deimination occurs at Arg3 of the N-terminal sequence acetyl-SGRGK
-
-
?
histone H4-L-arginine + H2O
histone H4-L-citrulline + NH3
histone L-arginine + H2O
histone L-citrulline + NH3
IEIITDRQSGKKR + H2O
?
substrate for isoform PAD2
-
-
?
IEIMTDRGSGKKR + H2O
?
substrate for isoform PAD2
-
-
?
IGSRGDRSGFGKF + H2O
?
substrate for isoform PAD2
-
-
?
keratin L-arginine + H2O
keratin L-citrulline + NH3
keratin-L-arginine + H2O
keratin-L-citrulline + NH3
KKSIRDTPA + H2O
KKSI-citrulline-DTPA
-
-
-
?
KSIRDTP + H2O
KSI-citrulline-DTP
-
-
-
?
myelin basic protein L-arginine + H2O
myelin basic protein L-citrulline + NH3
myelin basic protein-L-arginine + H2O
myelin basic protein-L-citrulline + NH3
N-alpha-benzoyl-L-arginine amide + H2O
N-alpha-benzoyl-L-citrulline amide + NH3
-
best small molecule substrate for isozyme PAD1
-
-
?
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline ethyl ester + NH3
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline methyl ester + NH3
-
-
-
?
N-alpha-benzoyl-L-arginine methyl ester + H2O
N-alpha-benzoyl-L-citrulline methyl ester + NH3
-
-
-
-
?
Nalpha-benzoyl L-arginine ethyl ester + H2O
Nalpha-benzoyl L-citrulline ethyl ester + NH3
-
-
-
-
?
Nalpha-benzoyl-L-arginine + H2O
Nalpha-benzoyl-L-citrulline + NH3
Nalpha-benzoyl-L-arginine amide + H2O
Nalpha-benzoyl-L-citrulline amide + NH3
Nalpha-benzoyl-L-arginine ethyl ester
Nalpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
-
?
Nalpha-benzoyl-L-arginine ethyl ester + H2O
Nalpha-benzoyl-L-citrulline ethyl ester + NH3
Nalpha-benzoyl-L-arginine methyl ester + H2O
Nalpha-benzoyl-L-citrulline methyl ester + NH3
p300-L-arginine + H2O
?
-
-
-
-
?
PAD4-L-arginine + H2O
PAD4-L-citrulline + NH3
-
PAD4 is autodeiminated in a time-dependent manner
-
-
?
peptide H3-1-L-arginine + H2O
peptide H3-1-L-citrulline + NH3
i.e. Ac4KQTARKSTGG13
-
-
?
peptide H3-2-L-arginine + H2O
peptide H3-2-L-citrulline + NH3
i.e. Ac14KAPRKQLATK23
-
-
?
peptide H4-L-arginine + H2O
peptide H4-L-citrulline + NH3
-
i.e. Ac1SGRGKGGKGL10
-
?
protein L-Arg + H2O
protein citrulline + NH3
-
-
-
-
?
protein L-Arg + H2O
protein L-citrulline + NH3
peptidyl deiminase type II is the primary enzyme responsible for the conversion of protein bound arginine to citrulline in the central nervous system
-
-
?
protein L-Arg + H2O
protein-L-citrulline + NH3
-
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
protein-L-arginine + H2O
protein-L-citrulline + NH3
QLSLRTVSL + H2O
QLSL-citrulline-TVSL
-
-
-
?
S100A3-L-arginine + H2O
S100A3-L-citrulline + NH3
-
-
-
?
SHQESTRGKSKGKAAAAA + H2O
SHQEST-Cit-GKSKGKAAAAA + NH3
-
-
-
?
SIRDT + H2O
SI-citrulline-RDT
-
-
-
?
TKQTARKSTGGK + H2O
?
-
-
-
-
?
tosyl-Arg-ethyl ester + H2O
tosyl-citrulline-ethyl ester + NH3
-
hPADI2
-
-
?
TSTGGRQGSHH + H2O
?
-
-
-
-
?
vimentin-L-arginine + H2O
vimentin-L-citrulline + NH3
vimetin L-arginine + H2O
vimentin L-citrulline + NH3
[histone H4]-L-Arg + H2O
[histone H4]-L-citrulline + NH3
-
-
-
-
?
additional information
?
-
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
isoform PAD3
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
peptidylarginine deiminase 3
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
trichohyalin-L-arginine + H2O
trichohyalin-L-citrulline + NH3
PAD3, involvement in skin disease
-
-
ir
trichohyalin-L-arginine + H2O
trichohyalin-L-citrulline + NH3
PAD3
-
-
ir
acetyl-L-Arg methyl ester + H2O
acetyl-L-citrulline methyl ester + NH3
peptidylarginine deiminase 1
-
-
?
acetyl-L-Arg methyl ester + H2O
acetyl-L-citrulline methyl ester + NH3
peptidylarginine deiminase 2
-
-
?
benzoyl-Arg-ethyl ester + H2O
benzoyl-citrulline-ethyl ester + NH3
-
hPADI2
-
-
?
benzoyl-Arg-ethyl ester + H2O
benzoyl-citrulline-ethyl ester + NH3
-
hPADI4
-
-
?
benzoyl-Arg-methyl ester + H2O
benzoyl-citrulline-methyl ester + NH3
-
hPADI2
-
-
?
benzoyl-Arg-methyl ester + H2O
benzoyl-citrulline-methyl ester + NH3
-
hPADI4
-
-
?
benzoyl-Arg-NH2 + H2O
benzoyl-citrulline-NH2 + NH3
-
hPADI2
-
-
?
benzoyl-Arg-NH2 + H2O
benzoyl-citrulline-NH2 + NH3
-
hPADI4
-
-
?
benzoyl-L-Arg + H2O
benzoyl-L-citrulline + NH3
peptidylarginine deiminase 1
-
-
?
benzoyl-L-Arg + H2O
benzoyl-L-citrulline + NH3
peptidylarginine deiminase 2
-
-
?
benzoyl-L-Arg ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
-
-
-
-
?
benzoyl-L-Arg ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
peptidylarginine deiminase 1
-
-
?
benzoyl-L-Arg ethyl ester + H2O
benzoyl-L-citrulline ethyl ester + NH3
peptidylarginine deiminase 2
-
-
?
DSHKFDRDFIYSD + H2O
DSHKFDCitDFIYSD + NH3
79% conversion by isoform PAD4
-
-
?
DSHKFDRDFIYSD + H2O
DSHKFDCitDFIYSD + NH3
90% conversion by isoform PAD2
-
-
?
DSHKHSREWLWSD + H2O
DSHKHSCitEWLWSD + NH3
51% conversion by isoform PAD4
-
-
?
DSHKHSREWLWSD + H2O
DSHKHSCitEWLWSD + NH3
97% conversion by isoform PAD2
-
-
?
DSHKWHRDFFYSD + H2O
DSHKWHCitDFFYSD + NH3
73% conversion by isoform PAD4
-
-
?
DSHKWHRDFFYSD + H2O
DSHKWHCitDFFYSD + NH3
92% conversion by isoform PAD2
-
-
?
DSKFAFRGGIASD + H2O
DSKFAFCitGGIASD + NH3
25% conversion by isoform PAD4
-
-
?
DSKFAFRGGIASD + H2O
DSKFAFCitGGIASD + NH3
90% conversion by isoform PAD2
-
-
?
DSKFHFRYAVASD + H2O
DSKFHFCitYAVASD + NH3
92% conversion by isoform PAD2
-
-
?
DSKFHFRYAVASD + H2O
DSKFHFCitYAVASD + NH3
less than 20% conversion by isoform PAD4
-
-
?
DSKFKFRYAYASD + H2O
DSKFKFCitYAYASD + NH3
91% conversion by isoform PAD2
-
-
?
DSKFKFRYAYASD + H2O
DSKFKFCitYAYASD + NH3
less than 20% conversion by isoform PAD4
-
-
?
DSKHFHRDFIYSD + H2O
DSKHFHCitDFIYSD + NH3
69% conversion by isoform PAD4
-
-
?
DSKHFHRDFIYSD + H2O
DSKHFHCitDFIYSD + NH3
94% conversion by isoform PAD2
-
-
?
DSKHKSRDFVYSD + H2O
DSKHKSCitDFVYSD + NH3
69% conversion by isoform PAD4
-
-
?
DSKHKSRDFVYSD + H2O
DSKHKSCitDFVYSD + NH3
94% conversion by isoform PAD2
-
-
?
DSKHLSREWMWSD + H2O
DSKHLSCitEWMWSD + NH3
54% conversion by isoform PAD4
-
-
?
DSKHLSREWMWSD + H2O
DSKHLSCitEWMWSD + NH3
95% conversion by isoform PAD2
-
-
?
DSKKFDRDHLYSD + H2O
DSKKFDCitDHLYSD + NH3
77% conversion by isoform PAD4
-
-
?
DSKKFDRDHLYSD + H2O
DSKKFDCitDHLYSD + NH3
90% conversion by isoform PAD2
-
-
?
DSKKFDRGHLYSD + H2O
DSKKFDCitGHLYSD + NH3
80% conversion by isoform PAD4
-
-
?
DSKKFDRGHLYSD + H2O
DSKKFDCitGHLYSD + NH3
90% conversion by isoform PAD2
-
-
?
DSKKFHRDFLYSD + H2O
DSKKFHCitDFLYSD + NH3
64% conversion by isoform PAD4
-
-
?
DSKKFHRDFLYSD + H2O
DSKKFHCitDFLYSD + NH3
97% conversion by isoform PAD2
-
-
?
DSKKFHRGFLYSD + H2O
DSKKFHCitGFLYSD + NH3
100% conversion by isoform PAD2
-
-
?
DSKKFHRGFLYSD + H2O
DSKKFHCitGFLYSD + NH3
73% conversion by isoform PAD4
-
-
?
DSKKFKRDFLFSD + H2O
DSKKFKCitDFLFSD + NH3
35% conversion by isoform PAD4
-
-
?
DSKKFKRDFLFSD + H2O
DSKKFKCitDFLFSD + NH3
97% conversion by isoform PAD2
-
-
?
DSKKHDRDHLWSD + H2O
DSKKHDCitDHLWSD + NH3
80% conversion by isoform PAD4
-
-
?
DSKKHDRDHLWSD + H2O
DSKKHDCitDHLWSD + NH3
95% conversion by isoform PAD2
-
-
?
DSKKHFRDKLYSD + H2O
DSKKHFCitDKLYSD + NH3
37% conversion by isoform PAD4
-
-
?
DSKKHFRDKLYSD + H2O
DSKKHFCitDKLYSD + NH3
92% conversion by isoform PAD2
-
-
?
DSKKHFRGKLYSD + H2O
DSKKHFCitGKLYSD + NH3
22% conversion by isoform PAD4
-
-
?
DSKKHFRGKLYSD + H2O
DSKKHFCitGKLYSD + NH3
96% conversion by isoform PAD2
-
-
?
DSKKKHREWVWSD + H2O
DSKKKHCitEWVWSD + NH3
100% conversion by isoform PAD2
-
-
?
DSKKKHREWVWSD + H2O
DSKKKHCitEWVWSD + NH3
72% conversion by isoform PAD4
-
-
?
DSKKLHRDHMESD + H2O
DSKKLHCitDHMESD + NH3
65% conversion by isoform PAD4
-
-
?
DSKKLHRDHMESD + H2O
DSKKLHCitDHMESD + NH3
90% conversion by isoform PAD2
-
-
?
DSKKYDRDFLWSD + H2O
DSKKYDCitDFLWSD + NH3
76% conversion by isoform PAD4
-
-
?
DSKKYDRDFLWSD + H2O
DSKKYDCitDFLWSD + NH3
92% conversion by isoform PAD2
-
-
?
DSKKYDRGFLWSD + H2O
DSKKYDCitGFLWSD + NH3
81% conversion by isoform PAD4
-
-
?
DSKKYDRGFLWSD + H2O
DSKKYDCitGFLWSD + NH3
93% conversion by isoform PAD2
-
-
?
DSKWHHRDHLYSD + H2O
DSKWHHCitDHLYSD + NH3
71% conversion by isoform PAD4
-
-
?
DSKWHHRDHLYSD + H2O
DSKWHHCitDHLYSD + NH3
90% conversion by isoform PAD2
-
-
?
DSKWHHRGHLYSD + H2O
DSKWHHCitGHLYSD + NH3
71% conversion by isoform PAD4
-
-
?
DSKWHHRGHLYSD + H2O
DSKWHHCitGHLYSD + NH3
96% conversion by isoform PAD2
-
-
?
DSKWYHRNKFWSD + H2O
DSKWYHCitNKFWSD + NH3
45% conversion by isoform PAD4
-
-
?
DSKWYHRNKFWSD + H2O
DSKWYHCitNKFWSD + NH3
98% conversion by isoform PAD2
-
-
?
DSQFAFRGASASD + H2O
DSQFAFCitGASASD + NH3
less than 20% conversion by isoform PAD2
-
-
?
DSQFAFRGASASD + H2O
DSQFAFCitGASASD + NH3
less than 20% conversion by isoform PAD4
-
-
?
DSQWAFRHALFSD + H2O
DSQWAFCitHALFSD + NH3
95% conversion by isoform PAD2
-
-
?
DSQWAFRHALFSD + H2O
DSQWAFCitHALFSD + NH3
less than 20% conversion by isoform PAD4
-
-
?
FFDSHKFDRDFIYSD + H2O
FFDSHKFDCitDFIYSD + NH3
94% conversion by isoform PAD4
-
-
?
FFDSHKFDRDFIYSD + H2O
FFDSHKFDCitDFIYSD + NH3
97% conversion by isoform PAD2
-
-
?
FFDSHKHSREWLWSD + H2O
FFDSHKHSCitEWLWSD + NH3
22% conversion by isoform PAD4
-
-
?
FFDSHKHSREWLWSD + H2O
FFDSHKHSCitEWLWSD + NH3
96% conversion by isoform PAD2
-
-
?
FFDSHKKSREYVFSD + H2O
FFDSHKKSCitEYVFSD + NH3
100% conversion by isoform PAD2
-
-
?
FFDSHKKSREYVFSD + H2O
FFDSHKKSCitEYVFSD + NH3
58% conversion by isoform PAD4
-
-
?
FFDSHKLHREWMWSD + H2O
FFDSHKLHCitEWMWSD + NH3
91% conversion by isoform PAD4
-
-
?
FFDSHKLHREWMWSD + H2O
FFDSHKLHCitEWMWSD + NH3
92% conversion by isoform PAD2
-
-
?
FFDSHKWHRDFFYSD + H2O
FFDSHKWHCitDFFYSD + NH3
88% conversion by isoform PAD4
-
-
?
FFDSHKWHRDFFYSD + H2O
FFDSHKWHCitDFFYSD + NH3
9% conversion by isoform PAD2
-
-
?
FFDSKHFDREWIWSD + H2O
FFDSKHFDCitEWIWSD + NH3
89% conversion by isoform PAD4
-
-
?
FFDSKHFDREWIWSD + H2O
FFDSKHFDCitEWIWSD + NH3
94% conversion by isoform PAD2
-
-
?
FFDSKHKSRDFVYSD + H2O
FFDSKHKSCitDFVYSD + NH3
77% conversion by isoform PAD4
-
-
?
FFDSKHKSRDFVYSD + H2O
FFDSKHKSCitDFVYSD + NH3
92% conversion by isoform PAD2
-
-
?
FFDSKHLSREWMWSD + H2O
FFDSKHLSCitEWMWSD + NH3
73% conversion by isoform PAD4
-
-
?
FFDSKHLSREWMWSD + H2O
FFDSKHLSCitEWMWSD + NH3
97% conversion by isoform PAD2
-
-
?
FFDSKKFSRDHIESD + H2O
FFDSKKFSCitDHIESD + NH3
63% conversion by isoform PAD4
-
-
?
FFDSKKFSRDHIESD + H2O
FFDSKKFSCitDHIESD + NH3
90% conversion by isoform PAD2
-
-
?
FFDSKKKHREWVWSD + H2O
FFDSKKKHCitEWVWSD + NH3
76% conversion by isoform PAD4
-
-
?
FFDSKKKHREWVWSD + H2O
FFDSKKKHCitEWVWSD + NH3
99% conversion by isoform PAD2
-
-
?
FFDSKKWSREYFFSD + H2O
FFDSKKWSCitEYFFSD + NH3
76% conversion by isoform PAD4
-
-
?
FFDSKKWSREYFFSD + H2O
FFDSKKWSCitEYFFSD + NH3
94% conversion by isoform PAD2
-
-
?
fibrin L-arginine + H2O
fibrin L-citrulline + NH3
-
-
-
-
?
fibrin L-arginine + H2O
fibrin L-citrulline + NH3
-
citrullinated fibrin is a potential antigen of rheumatoid arthritis
-
-
?
Fibrinogen + H2O
?
-
human fibrinogen, hPADI2
-
-
?
Fibrinogen + H2O
?
-
human fibrinogen, hPADI4
-
-
?
fibrinogen-L-arginine + H2O
fibrinogen-L-citrulline + NH3
PAD4, involvement in rheumatoid arthritis
-
-
ir
fibrinogen-L-arginine + H2O
fibrinogen-L-citrulline + NH3
PAD4
-
-
ir
filaggrin + H2O
?
-
human filaggrin, hPADI2
-
-
?
filaggrin + H2O
?
-
human filaggrin, hPADI4
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
isoform PAD1
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
isoform PAD3
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
peptidylarginine deiminase 1
-
-
?
filaggrin L-arginine + H2O
filaggrin L-citrulline + NH3
peptidylarginine deiminase 2
-
-
?
filaggrin-L-arginine + H2O
filaggrin-L-citrulline + NH3
PAD4, involvement in rheumatoid arthritis
-
-
ir
filaggrin-L-arginine + H2O
filaggrin-L-citrulline + NH3
PAD4
-
-
ir
glial fibrillary acidic protein-L-arginine + H2O
glial fibrillary acidic protein-L-citrulline + NH3
PAD2, involvement in Alzheimer's diease
-
-
ir
glial fibrillary acidic protein-L-arginine + H2O
glial fibrillary acidic protein-L-citrulline + NH3
PAD2
-
-
ir
histone H2A-L-arginine + H2O
histone H2A-L-citrulline + NH3
-
-
-
-
?
histone H2A-L-arginine + H2O
histone H2A-L-citrulline + NH3
PAD4, involvement in rheumatoid arthritis
-
-
ir
histone H2A-L-arginine + H2O
histone H2A-L-citrulline + NH3
PAD4
-
-
ir
histone H3-L-Arg + H2O
histone H3-L-citrulline
-
PADI4 is a histone H3-specific arginine deiminase. Deimination is a mechanism for antagonizing the transcriptional induction mediated by arginine methylation
-
-
?
histone H3-L-Arg + H2O
histone H3-L-citrulline
-
PADI4 is a histone H3-specific arginine deiminase
-
-
?
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
-
-
-
-
?
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
-
-
-
?
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
PAD4, involvement in rheumatoid arthritis
-
-
ir
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
PAD4
-
-
ir
histone H3-L-arginine + H2O
histone H3-L-citrulline + NH3
PAD4 interacts with p53 and is recruited to the p21 promoter to regulate histone H3 L-Arg methylation and citrullination
-
-
?
histone H4-L-arginine + H2O
histone H4-L-citrulline + NH3
-
-
-
-
?
histone H4-L-arginine + H2O
histone H4-L-citrulline + NH3
PAD4, involvement in rheumatoid arthritis
-
-
ir
histone H4-L-arginine + H2O
histone H4-L-citrulline + NH3
PAD4
-
-
ir
histone H4-L-arginine + H2O
histone H4-L-citrulline + NH3
-
isozyme PAD4 deiminates histone H4 at arginines 3, 17, and 19 in vitro and arginine 3 in vivo
-
-
?
histone L-arginine + H2O
histone L-citrulline + NH3
-
-
-
-
?
histone L-arginine + H2O
histone L-citrulline + NH3
-
PAD4 mediates gene expression by regulating Arg methylation and citrullination in histones
-
-
?
keratin L-arginine + H2O
keratin L-citrulline + NH3
peptidylarginine deiminase 1
-
-
?
keratin L-arginine + H2O
keratin L-citrulline + NH3
peptidylarginine deiminase 2
-
-
?
keratin-L-arginine + H2O
keratin-L-citrulline + NH3
PAD1
-
-
ir
keratin-L-arginine + H2O
keratin-L-citrulline + NH3
PAD2, involvement in psoriasis
-
-
ir
keratin-L-arginine + H2O
keratin-L-citrulline + NH3
PAD2
-
-
ir
myelin basic protein L-arginine + H2O
myelin basic protein L-citrulline + NH3
-
-
-
-
?
myelin basic protein L-arginine + H2O
myelin basic protein L-citrulline + NH3
-
-
-
?
myelin basic protein L-arginine + H2O
myelin basic protein L-citrulline + NH3
PAD2 overexpression in brain of transgenic mice leads to myelin loss in the central nervous system
-
-
?
myelin basic protein-L-arginine + H2O
myelin basic protein-L-citrulline + NH3
-
PAD2 and PAD4 are involved in the pathogenesis of demyelination diseases such as multiple sclerosis, overview
-
-
?
myelin basic protein-L-arginine + H2O
myelin basic protein-L-citrulline + NH3
PAD2, involvement in multiple sclerosis
-
-
ir
myelin basic protein-L-arginine + H2O
myelin basic protein-L-citrulline + NH3
-
amino acid sequence determination of the substrate protein by LC/MS, PAD2 deiminates 18 of 19 arginyl residues, whereas PAD4 deiminates 14 of 19 arginyl residues, determination of deimination residues, overview
-
-
?
myelin basic protein-L-arginine + H2O
myelin basic protein-L-citrulline + NH3
PAD2
-
-
ir
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
-
?
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
?
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
?
N-alpha-benzoyl-L-arginine ethyl ester + H2O
N-alpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
-
?
Nalpha-benzoyl-L-arginine + H2O
Nalpha-benzoyl-L-citrulline + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine + H2O
Nalpha-benzoyl-L-citrulline + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine amide + H2O
Nalpha-benzoyl-L-citrulline amide + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine amide + H2O
Nalpha-benzoyl-L-citrulline amide + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine ethyl ester + H2O
Nalpha-benzoyl-L-citrulline ethyl ester + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine ethyl ester + H2O
Nalpha-benzoyl-L-citrulline ethyl ester + NH3
100% activity
-
-
?
Nalpha-benzoyl-L-arginine ethyl ester + H2O
Nalpha-benzoyl-L-citrulline ethyl ester + NH3
100% activity
-
-
?
Nalpha-benzoyl-L-arginine methyl ester + H2O
Nalpha-benzoyl-L-citrulline methyl ester + NH3
-
-
-
?
Nalpha-benzoyl-L-arginine methyl ester + H2O
Nalpha-benzoyl-L-citrulline methyl ester + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein L-arginine + H2O
protein L-citrulline + NH3
-
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
-
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
-
-
ir
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
citrullination of proteins may exert a specific role in the course of PNS development and repair
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
PAD1
-
-
ir
protein-L-arginine + H2O
protein-L-citrulline + NH3
PAD4 is a transcriptional coregulator that catalyzes the calcium-dependent conversion of specific arginine residues in proteins to citrulline and plays a role in the onset and progression of the chronic autoimmune disorder rheumatoid arthritis
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
-
posttranslational convertion, PADI4 plays an essential role in immune cell differentiation and apoptosis, ionomycin-inducible PADI4-decreased cell viability and PADI4-enhanced apoptosis, overview
-
-
?
protein-L-arginine + H2O
protein-L-citrulline + NH3
development and evaluation of a highly sensitive antibody-based assay method for PAD activity determination, overview
-
-
?
vimentin-L-arginine + H2O
vimentin-L-citrulline + NH3
-
-
-
-
?
vimentin-L-arginine + H2O
vimentin-L-citrulline + NH3
PAD2, involvement in Alzheimer's disease
-
-
ir
vimentin-L-arginine + H2O
vimentin-L-citrulline + NH3
PAD2
-
-
ir
vimetin L-arginine + H2O
vimentin L-citrulline + NH3
peptidylarginine deiminase 2
-
-
?
vimetin L-arginine + H2O
vimentin L-citrulline + NH3
peptidylarginine deiminase 4
-
-
?
additional information
?
-
PADI3 expression is driven by Sp1/Sp3 and NF-Y binding to the promoter region
-
-
?
additional information
?
-
-
PADI3 expression is driven by Sp1/Sp3 and NF-Y binding to the promoter region
-
-
?
additional information
?
-
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
-
abnormal accumulation of citrullinated proteins and abnormal activation of PAD2 in hippocampi of patients with Alzheimer's disease, strongly suggests that peptidylarginine deiminase has an important role in the onset and progression of abnormal accumulation of citrullinated proteins and abnormal activation of PAD2 in hippocampi of Alzheimer's disease
-
-
?
additional information
?
-
peptidylarginine deiminase type 4 plays an essential role in pathogenesis of rheumatoid arthritis.Peptidylarginine deiminase type 4 may contribute to the disrupted apoptosis of tumors by caspase-mediated claevage of cytokeratin
-
-
?
additional information
?
-
-
the enzyme catalyzes post-translational modification of protein through the conversion of arginine to citrulline in the presence of calcium ions. Peptidylarginine deiminase-mediated deimination of epithelial cell keratin resulting in cytoskeletal remodeling suggests a possible role for hPADVI in cytoskeletal reorganization in the egg and in early embryo development
-
-
?
additional information
?
-
methylated Arg residues are quite poor substrates for full-length PAD4 in vitro, regardless of whether this residue is in the context of a small molecule or a peptide substrate
-
-
?
additional information
?
-
-
methylated Arg residues are quite poor substrates for full-length PAD4 in vitro, regardless of whether this residue is in the context of a small molecule or a peptide substrate
-
-
?
additional information
?
-
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis
-
-
?
additional information
?
-
-
the enzyme is involved in autoimmune rheumatoid arthritis, isozyme PAD2 is also implicated in neurological diseases with or without ocular manifestations, e.g. multiple sclerosis, autoimmune encephalomyelitis, Alzheimer's disease, and glaucoma
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis, isozyme PAD2 is also implicated in neurological diseases with or without ocular manifestations, e.g. multiple sclerosis, autoimmune encephalomyelitis, Alzheimer's disease, and glaucoma
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis, isozyme PAD2 is also implicated in neurological diseases with or without ocular manifestations, e.g. multiple sclerosis, autoimmune encephalomyelitis, Alzheimer's disease, and glaucoma
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis, isozyme PAD2 is also implicated in neurological diseases with or without ocular manifestations, e.g. multiple sclerosis, autoimmune encephalomyelitis, Alzheimer's disease, and glaucoma
-
-
?
additional information
?
-
the enzyme is involved in autoimmune rheumatoid arthritis, isozyme PAD2 is also implicated in neurological diseases with or without ocular manifestations, e.g. multiple sclerosis, autoimmune encephalomyelitis, Alzheimer's disease, and glaucoma
-
-
?
additional information
?
-
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, e.g. PAD2 in glaucoma of the optic nerve, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, e.g. PAD2 in glaucoma of the optic nerve, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, e.g. PAD2 in glaucoma of the optic nerve, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, e.g. PAD2 in glaucoma of the optic nerve, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, e.g. PAD2 in glaucoma of the optic nerve, overview
-
-
?
additional information
?
-
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
no activity with free L-arginine, which is converted by EC 1.14.13.39, nitric oxide synthase, the enzyme is not identical with bacterial arginine deiminase, EC 3.5.3.6, PADs are involved in diverse diseases, overview
-
-
?
additional information
?
-
-
substrate binding structure, sequence specificity, overview
-
-
?
additional information
?
-
substrate binding structure, sequence specificity, overview
-
-
?
additional information
?
-
-
a methylated lysine residue flanking the targeted arginine influences PAD-4-mediated deimination
-
-
?
additional information
?
-
does not citrullinate interleukin-1beta
-
-
?
additional information
?
-
does not citrullinate interleukin-1beta
-
-
?
additional information
?
-
-
no activity toward PVRAK, DQRTA, DVRIA, and EPRLF
-
-
?
additional information
?
-
-
the binding affinity of autodeiminated PAD4 for p53 and H3 are similar to non-deiminated PAD4. In contrast, the affinity of autodeiminated PAD4 for HDAC1, PRMT1, and Cit H3 is reduced by 3.7, 4.5, and 10fold, respectively. Results suggest that the autodeimination of PAD4 in vivo could affect its functional activity by regulating its ability to interact with binding partners
-
-
?
additional information
?
-
-
possible 14-3-3 protein binding sites in human PAD6 are identified by in silico methods. Two of these sites are confirmed as 14-3-3 binding sites by fluorescence polarization competition and X-ray crystallography
-
-
?
additional information
?
-
nearly no activity with free L-arginine, L-agmatine, histone H3, and histone H4
-
-
?
additional information
?
-
isoform PAD2 appears to favor citrullination of glycine-containing motifs. Distinct hydrophobic motifs are identified for PAD2 citrullination sites predicted to reside within alpha-helical and beta-sheet regions. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
additional information
?
-
isoform PAD2 appears to favor citrullination of glycine-containing motifs. Distinct hydrophobic motifs are identified for PAD2 citrullination sites predicted to reside within alpha-helical and beta-sheet regions. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
additional information
?
-
-
isoform PAD2 appears to favor citrullination of glycine-containing motifs. Distinct hydrophobic motifs are identified for PAD2 citrullination sites predicted to reside within alpha-helical and beta-sheet regions. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
additional information
?
-
isoform PAD4 appears to favor citrullination of glycine-containing motifs. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
additional information
?
-
isoform PAD4 appears to favor citrullination of glycine-containing motifs. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
additional information
?
-
-
isoform PAD4 appears to favor citrullination of glycine-containing motifs. There is potential substrate overlap between coil region citrullination and arginine methylation
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acute Kidney Injury
ATP induces PAD4 in renal proximal tubule cells via P2X7 receptor activation to exacerbate ischemic AKI.
Acute Kidney Injury
Divergent roles for kidney proximal tubule and granulocyte PAD4 in ischemic AKI.
Acute Kidney Injury
Evaluation of peptidylarginine deiminase 4 and PADI4 polymorphisms in sepsis-induced acute kidney injury.
Adenocarcinoma
DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth.
Adenocarcinoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Adenocarcinoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Adenocarcinoma
Investigating the pathogenic role of PADI4 in oesophageal cancer.
Adenocarcinoma
PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.
Adenocarcinoma
Putative Roles for Peptidylarginine Deiminases in COVID-19.
Adenocarcinoma of Lung
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Adenocarcinoma, Papillary
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Adenoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Alopecia
Autosomal-Dominant Mutation in PADI3 Responsible for up to 25% of Central Centrifugal Cicatricial Alopecia Cases.
Alopecia
Comprehensive analysis of protein expression levels and phosphorylation levels in host skin in response to tick (Haemaphysalis longicornis) bite.
Alopecia
Mapping of cis-acting expression quantitative trait loci in human scalp hair follicles.
Alopecia
Variant PADI3 in Central Centrifugal Cicatricial Alopecia.
Alveolar Bone Loss
Induction of immune response and prevention of alveolar bone loss with recombinant Porphyromonas gingivalis peptidylarginine deiminase.
Alzheimer Disease
A two-stage case-control association study of PADI2 with schizophrenia.
Alzheimer Disease
Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease.
Alzheimer Disease
Arginine Metabolising Enzymes as Therapeutic Tools for Alzheimer's Disease: Peptidyl Arginine Deiminase Catalyses Fibrillogenesis of beta-amyloid Peptides.
Alzheimer Disease
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Alzheimer Disease
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Alzheimer Disease
Peptidyl arginine deiminase 4 and its potential role in Alzheimer's disease.
Anemia, Sickle Cell
Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vaso-occlusive crisis.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Significance of serum peptidylarginine deiminase type 4 in ANCA-associated vasculitis.
Aortic Aneurysm, Abdominal
Inhibition of Peptidyl Arginine Deiminase 4-Dependent Neutrophil Extracellular Trap Formation Reduces Angiotensin II-Induced Abdominal Aortic Aneurysm Rupture in Mice.
Appendicitis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Arthritis
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice.
Arthritis
Effect of Porphyromonas gingivalis infection on gut dysbiosis and resultant arthritis exacerbation in mouse model.
Arthritis
Epitope-Based Chicken-Derived Novel Anti-PAD2 Monoclonal Antibodies Inhibit Citrullination.
Arthritis
Extracellular citrullination inhibits the function of matrix associated TGF-?.
Arthritis
Extracellular traps and PAD4 released by macrophages induce citrullination and auto-antibody production in autoimmune arthritis.
Arthritis
Genetics of arthritis severity: A genome-wide and species-wide dissection in HS mice.
Arthritis
Insights into the significance of peptidylarginine deiminase 4 and antibodies against citrullinated antigens in the absence of "true ACPAs" in an experimental model of arthritis: comment on the article by Shelef et al.
Arthritis
Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis.
Arthritis
PADI4 (rs2240340), PDCD1 (rs10204525), and CTLA4 (231775) Gene Polymorphisms and Polyarticular Juvenile Idiopathic Arthritis.
Arthritis
PADI4 and the HLA-DRB1 shared epitope in juvenile idiopathic arthritis.
Arthritis
Peptidyl arginine deiminase inhibition suppresses arthritis via decreased protein citrullination in joints and serum with the downregulation of interlukin-6.
Arthritis
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.
Arthritis
Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.
Arthritis
Peptidylarginine deiminase 4 contributes to tumor necrosis factor alpha induced inflammatory arthritis.
Arthritis
Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model.
Arthritis
Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene.
Arthritis
Periarticular Bone Loss in Arthritis Is Induced by Autoantibodies Against Citrullinated Vimentin.
Arthritis
Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD).
Arthritis
Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis.
Arthritis
Reduced Anti-Histone Antibodies and Increased Risk of Rheumatoid Arthritis Associated with a Single Nucleotide Polymorphism in PADI4 in North Americans.
Arthritis
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
Arthritis
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation.
Arthritis, Experimental
Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses.
Arthritis, Experimental
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
Arthritis, Experimental
N-{alpha}-Benzoyl-N5-(2-Chloro-1-Iminoethyl)-L-Ornithine Amide, a Protein Arginine Deiminase Inhibitor, Reduces the Severity of Murine Collagen-Induced Arthritis.
Arthritis, Experimental
Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis.
Arthritis, Experimental
The regulation of macrophage polarization by hypoxia-PADI4 coordination in Rheumatoid arthritis.
Arthritis, Juvenile
PADI4 (rs2240340), PDCD1 (rs10204525), and CTLA4 (231775) Gene Polymorphisms and Polyarticular Juvenile Idiopathic Arthritis.
Arthritis, Juvenile
PADI4 and the HLA-DRB1 shared epitope in juvenile idiopathic arthritis.
Arthritis, Juvenile
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
Arthritis, Rheumatoid
A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population.
Arthritis, Rheumatoid
A fluopol-ABPP HTS assay to identify PAD inhibitors.
Arthritis, Rheumatoid
A functional haplotype and expression of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Chinese.
Arthritis, Rheumatoid
A Functional Haplotype of PADI4 Gene in Rheumatoid Arthritis: Positive Correlation in a French Population.
Arthritis, Rheumatoid
A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans.
Arthritis, Rheumatoid
A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population.
Arthritis, Rheumatoid
Active site cysteine is protonated in the PAD4 Michaelis complex: evidence from Born-Oppenheimer ab initio QM/MM molecular dynamics simulations.
Arthritis, Rheumatoid
Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Arthritis, Rheumatoid
Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system.
Arthritis, Rheumatoid
Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate.
Arthritis, Rheumatoid
Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Arthritis, Rheumatoid
Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis - new pathways to epitope spreading.
Arthritis, Rheumatoid
Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis.
Arthritis, Rheumatoid
Association between PADI4 and rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
Association between PADI4 and rheumatoid arthritis: a replication study.
Arthritis, Rheumatoid
Association between PADI4 gene polymorphisms and anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis in a large Chinese Han cohort.
Arthritis, Rheumatoid
Association between peptidyl arginine deiminase 4 (PADI4)-104C/T polymorphism and rheumatoid arthritis: a meta-analysis in the Chinese population.
Arthritis, Rheumatoid
Association between Peptidylarginine Deiminase Type 4 rs1748033 Polymorphism and Susceptibility to Rheumatoid Arthritis in Zahedan, Southeast Iran.
Arthritis, Rheumatoid
Association between susceptibility to rheumatoid arthritis and PADI4 polymorphisms: a meta-analysis.
Arthritis, Rheumatoid
Association between the PADI4 -94G/A polymorphism and rheumatoid arthritis: a meta-analysis in the Chinese population.
Arthritis, Rheumatoid
Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis.
Arthritis, Rheumatoid
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Arthritis, Rheumatoid
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.
Arthritis, Rheumatoid
Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis.
Arthritis, Rheumatoid
Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
Arthritis, Rheumatoid
Association of MiRNA-146a, MiRNA-499, IRAK1 and PADI4 Polymorphisms with Rheumatoid Arthritis in Egyptian Population.
Arthritis, Rheumatoid
Association of PADI4 and rheumatoid arthritis: a successful multidisciplinary approach.
Arthritis, Rheumatoid
Association of single nucleotide polymorphisms (SNPs) of PADI4 gene with rheumatoid arthritis (RA) in Indian population.
Arthritis, Rheumatoid
Associations Between PADI4 Gene Polymorphisms and Rheumatoid Arthritis: An Updated Meta-analysis.
Arthritis, Rheumatoid
Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Autoantibodies to protein-arginine deiminase (PAD) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine.
Arthritis, Rheumatoid
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis.
Arthritis, Rheumatoid
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Arthritis, Rheumatoid
Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
Citrullination by peptidylarginine deiminase in rheumatoid arthritis.
Arthritis, Rheumatoid
Citrullination in the periodontium-a possible link between periodontitis and rheumatoid arthritis.
Arthritis, Rheumatoid
Citrullination of fibronectin alters integrin clustering and focal adhesion stability promoting stromal cell invasion.
Arthritis, Rheumatoid
Citrullination of fibronectin in rheumatoid arthritis synovial tissue.
Arthritis, Rheumatoid
Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Citrullinome of Porphyromonas gingivalis Outer Membrane Vesicles: Confident Identification of Citrullinated Peptides.
Arthritis, Rheumatoid
Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Arthritis, Rheumatoid
Contact with stimulated T cells up-regulates expression of peptidylarginine deiminase 2 and 4 by human monocytes.
Arthritis, Rheumatoid
Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism.
Arthritis, Rheumatoid
Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis.
Arthritis, Rheumatoid
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice.
Arthritis, Rheumatoid
Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology.
Arthritis, Rheumatoid
Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen.
Arthritis, Rheumatoid
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study.
Arthritis, Rheumatoid
Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Arthritis, Rheumatoid
Erratum to: PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-alpha-promoted transfactors activator protein-1, nuclear factor-Y, and Sp1.
Arthritis, Rheumatoid
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Arthritis, Rheumatoid
Evaluation of allele frequencies in the PADI4 gene and anti-cyclic citrullinated peptide antibodies of patients with rheumatoid arthritis in a Japanese population.
Arthritis, Rheumatoid
Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.
Arthritis, Rheumatoid
Expression of PADI4 in patients with ankylosing spondylitis and its role in mediating the effects of TNF-? on the proliferation and osteogenic differentiation of human mesenchymal stem cells.
Arthritis, Rheumatoid
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
Arthritis, Rheumatoid
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps.
Arthritis, Rheumatoid
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.
Arthritis, Rheumatoid
Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anticitrullinated protein antibodies.
Arthritis, Rheumatoid
Galectin-9 Is a Possible Promoter of Immunopathology in Rheumatoid Arthritis by Activation of Peptidyl Arginine Deiminase 4 (PAD-4) in Granulocytes.
Arthritis, Rheumatoid
Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.
Arthritis, Rheumatoid
Genetic and genomic studies of PADI4 in rheumatoid arthritis.
Arthritis, Rheumatoid
Genetic background of anticyclic citrullinated Peptide autoantibody production in hungarian patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Genomic modulators of gene expression in human neutrophils.
Arthritis, Rheumatoid
Great Therapeutic Potential of Peptidylarginine Deiminase 4 (PAD4) Inhibitors: Treatment of Rheumatoid Arthritis, Epigenetic Tools, Regulation of Pluripotency in Stem Cells, and More.
Arthritis, Rheumatoid
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.
Arthritis, Rheumatoid
Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population.
Arthritis, Rheumatoid
Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis.
Arthritis, Rheumatoid
Heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis in Koreans.
Arthritis, Rheumatoid
High variability of peptidylarginine deiminase 4 (PADI4) in a healthy white population: characterization of six new variants of PADI4 exons 2-4 by a novel haplotype-specific sequencing-based approach.
Arthritis, Rheumatoid
High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
Arthritis, Rheumatoid
Hypoxia?induced autophagy is inhibited by PADI4 knockdown, which promotes apoptosis of fibroblast?like synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis.
Arthritis, Rheumatoid
Increased levels of peptidylarginine deiminase 2 in synovial fluid from anti-CCP-positive rheumatoid arthritis patients: Association with disease activity and inflammatory markers.
Arthritis, Rheumatoid
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.
Arthritis, Rheumatoid
Insight into Neutrophil Extracellular Traps through Systematic Evaluation of Citrullination and Peptidylarginine Deiminases.
Arthritis, Rheumatoid
Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis.
Arthritis, Rheumatoid
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis.
Arthritis, Rheumatoid
Lack of Association among Peptidyl Arginine Deiminase Type 4 Autoantibodies, PADI4 Polymorphisms, and Clinical Characteristics in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Lack of association between PADI4 and functional severity in Japanese rheumatoid arthritis patients.
Arthritis, Rheumatoid
Lack of association between PADI4 polymorphisms and rheumatoid arthritis in the Tunisian population.
Arthritis, Rheumatoid
Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis.
Arthritis, Rheumatoid
Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of peptide citrullination site using Br signature.
Arthritis, Rheumatoid
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Arthritis, Rheumatoid
Meta-analysis of the association between PADI4 -92C/G polymorphism and rheumatoid arthritis in the Chinese population.
Arthritis, Rheumatoid
Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis.
Arthritis, Rheumatoid
Methylation of the guanidino group of arginine residues prevents citrullination by peptidylarginine deiminase IV.
Arthritis, Rheumatoid
Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe?
Arthritis, Rheumatoid
NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese.
Arthritis, Rheumatoid
Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis.
Arthritis, Rheumatoid
PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis.
Arthritis, Rheumatoid
PADI2 is significantly associated with rheumatoid arthritis.
Arthritis, Rheumatoid
PADI2 Polymorphisms Are Significantly Associated With Rheumatoid Arthritis, Autoantibodies Serologic Status and Joint Damage in Women from Southern Mexico.
Arthritis, Rheumatoid
PADI4 (rs2240340), PDCD1 (rs10204525), and CTLA4 (231775) Gene Polymorphisms and Polyarticular Juvenile Idiopathic Arthritis.
Arthritis, Rheumatoid
PADI4 and the HLA-DRB1 shared epitope in juvenile idiopathic arthritis.
Arthritis, Rheumatoid
PADI4 Epigenetically Suppresses p21 Transcription and Inhibits Cell Apoptosis in Fibroblast-like Synoviocytes from Rheumatoid Arthritis Patients.
Arthritis, Rheumatoid
PADI4 Gene Polymorphism is not Associated with Ankylosing Spondylitis in Chinese Han Population.
Arthritis, Rheumatoid
PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian Population.
Arthritis, Rheumatoid
PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation.
Arthritis, Rheumatoid
PADI4 polymorphism predisposes male smokers to rheumatoid arthritis.
Arthritis, Rheumatoid
PADI4 polymorphisms and related haplotype in rheumatoid arthritis patients.
Arthritis, Rheumatoid
PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.
Arthritis, Rheumatoid
PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
PADI4 polymorphisms and the functional haplotype are associated with increased rheumatoid arthritis susceptibility: A replication study in a Southern Mexican population.
Arthritis, Rheumatoid
PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population.
Arthritis, Rheumatoid
PADI4 Polymorphisms in Iranian Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Arthritis, Rheumatoid
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Arthritis, Rheumatoid
Peptidyl arginine deiminase autoimmunity and the development of ACPA in rheumatoid arthritis. The "hapten carrier" model.
Arthritis, Rheumatoid
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.
Arthritis, Rheumatoid
Peptidyl Arginine Deiminase Type 4 Gene Promoter Hypo-Methylation in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study.
Arthritis, Rheumatoid
Peptidyl arginine deiminase: A novel immunohistochemical marker for liver fibrosis in patients with chronic hepatitis.
Arthritis, Rheumatoid
Peptidyl-arginine deiminase: an additional marker of rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase 4 -104C/T polymorphism and risk of rheumatoid arthritis: A pooled analysis based on different populations.
Arthritis, Rheumatoid
Peptidylarginine deiminase 4 and citrullination in health and disease.
Arthritis, Rheumatoid
Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and ?-enolase: implications for autoimmunity in rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase type 2 and 4 generate distinct patterns of rheumatoid arthritis autoantigens during perforin-induced cell damage.
Arthritis, Rheumatoid
Peptidylarginine deiminase type 4 and methyl-CpG binding domain 4 polymorphisms in Chinese patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model.
Arthritis, Rheumatoid
Peptidylarginine deiminase type 4, anticitrullinated peptide antibodies, and rheumatoid arthritis.
Arthritis, Rheumatoid
Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene.
Arthritis, Rheumatoid
Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome.
Arthritis, Rheumatoid
Periodontal Treatment Decreases Levels of Antibodies to Porphyromonas Gingivalis and Citrulline in Patients With Rheumatoid Arthritis and Periodontitis.
Arthritis, Rheumatoid
Perspective on Protein Arginine Deiminase Activity-Bicarbonate Is a pH-Independent Regulator of Citrullination.
Arthritis, Rheumatoid
Polymorphisms and functional haplotype in PADI4: Further evidence for contribution on rheumatoid arthritis susceptibility and anti-cyclic citrullinated peptide antibodies in a western Mexican population.
Arthritis, Rheumatoid
Polymorphisms in peptidylarginine deiminase associate with rheumatoid arthritis in diverse Asian populations: evidence from MyEIRA study and meta-analysis.
Arthritis, Rheumatoid
Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis.
Arthritis, Rheumatoid
Prevalence of functional haplotypes of the peptidylarginine deiminase citrullinating enzyme gene in patients with rheumatoid arthritis: no influence of the presence of anti-citrullinated peptide antibodies.
Arthritis, Rheumatoid
Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4.
Arthritis, Rheumatoid
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.
Arthritis, Rheumatoid
Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis.
Arthritis, Rheumatoid
Protein arginine deiminase 4: evidence for a reverse protonation mechanism.
Arthritis, Rheumatoid
Proteolysis by Granzyme B Enhances Presentation of Autoantigenic Peptidylarginine Deiminase 4 Epitopes in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Reduced Anti-Histone Antibodies and Increased Risk of Rheumatoid Arthritis Associated with a Single Nucleotide Polymorphism in PADI4 in North Americans.
Arthritis, Rheumatoid
Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.
Arthritis, Rheumatoid
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.
Arthritis, Rheumatoid
Replication of reported genetic associations of PADI4, FCRL3, SLC22A4 and RUNX1 genes with rheumatoid arthritis: results of an independent Japanese population and evidence from meta-analysis of East Asian studies.
Arthritis, Rheumatoid
Role of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation.
Arthritis, Rheumatoid
Serum antibody levels against Porphyromonas gingivalis in patients with and without rheumatoid arthritis - a systematic review and meta-analysis.
Arthritis, Rheumatoid
Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
Arthritis, Rheumatoid
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Arthritis, Rheumatoid
Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.
Arthritis, Rheumatoid
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Arthritis, Rheumatoid
The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels.
Arthritis, Rheumatoid
The development of N-?-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-?-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.
Arthritis, Rheumatoid
The expression of mRNA for peptidylarginine deiminase type 2 and type 4 in bone marrow CD34+ cells in rheumatoid arthritis.
Arthritis, Rheumatoid
The expression of PADI4 in synovium of rheumatoid arthritis.
Arthritis, Rheumatoid
The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells.
Arthritis, Rheumatoid
The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis.
Arthritis, Rheumatoid
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin.
Arthritis, Rheumatoid
The PADI4 gene does not contribute to genetic susceptibility to rheumatoid arthritis in Chinese Han population.
Arthritis, Rheumatoid
The regulation of macrophage polarization by hypoxia-PADI4 coordination in Rheumatoid arthritis.
Arthritis, Rheumatoid
The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Theoretical insights into the protonation states of active site cysteine and citrullination mechanism of Porphyromonas gingivalis peptidylarginine deiminase.
Arthritis, Rheumatoid
There's no place like OM: Vesicular sorting and secretion of the peptidylarginine deiminase of Porphyromonas gingivalis.
Arthritis, Rheumatoid
Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Zinc is the modulator of the calcium-dependent activation of post-translationally acting thiol-enzymes in autoimmune diseases.
Arthritis, Rheumatoid
[Association between the synovial expression of cyclic citrullinated peptide and susceptibility variants of HLA-DRB1 shared epitope alleles and PADI 4 gene single nucleotide polymorphisms in patients with rheumatoid arthritis].
Arthritis, Rheumatoid
[Association of HLA-DR4, PAD4, and STAT4 expression in the peripheral blood with disease activity in patients with rheumatoid arthritis]
Arthritis, Rheumatoid
[Association of polymorphisms of PTPN22 and PADI4 genes with rheumatoid arthritis in Yunnan].
Arthritis, Rheumatoid
[Association of the PADI4 gene polymorphism and HLA-DRB1 shared epitope alleles with rheumatoid arthritis]
Arthritis, Rheumatoid
[Genetics and genomics in rheumatoid arthritis (RA): An update].
Arthritis, Rheumatoid
[Susceptibility genes in rheumatoid arthritis: peptidylarginine deiminase (PADI) type 4]
Arthritis, Rheumatoid
[The significance of serum peptidylarginine deiminase 4 in rheumatoid arthritis.]
Astrocytoma
Induction of peptidylarginine deiminase 2 and 3 by dibutyryl cAMP via cAMP-PKA signaling in human astrocytoma U-251MG cells.
Atherosclerosis
Myeloid-Specific Deletion of Peptidylarginine Deiminase 4 Mitigates Atherosclerosis.
Atherosclerosis
Neutrophils Cast NETs in Atherosclerosis: Employing Peptidylarginine Deiminase as a Therapeutic Target.
Atherosclerosis
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.
Atherosclerosis
The role of neutrophils in the pathogenesis of systemic lupus erythematosus.
Autoimmune Diseases
Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis.
Autoimmune Diseases
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.
Autoimmune Diseases
Cleavage Region Thyrotropin Receptor Antibodies Influence Thyroid Cell Survival In Vivo.
Autoimmune Diseases
Epitope-Based Chicken-Derived Novel Anti-PAD2 Monoclonal Antibodies Inhibit Citrullination.
Autoimmune Diseases
Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe?
Autoimmune Diseases
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Autoimmune Diseases
Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis.
Autoimmune Diseases
Perspective on Protein Arginine Deiminase Activity-Bicarbonate Is a pH-Independent Regulator of Citrullination.
Autoimmune Diseases
Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Autoimmune Diseases
Protein citrullination as a source of cancer neoantigens.
Autoimmune Diseases
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Autoimmune Diseases
Vimentin citrullination probed by a novel monoclonal antibody serves as a specific indicator for reactive astrocytes in neurodegeneration.
Brain Edema
Neutrophil Extracellular Traps may be a Potential Target for Treating Early Brain Injury in Subarachnoid Hemorrhage.
Breast Neoplasms
BB-Cl-Amidine as a novel therapeutic for canine and feline mammary cancer via activation of the endoplasmic reticulum stress pathway.
Breast Neoplasms
Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Breast Neoplasms
Endogenous PAD4 in Breast Cancer Cells Mediates Cancer Extracellular Chromatin Network Formation and Promotes Lung Metastasis.
Breast Neoplasms
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells.
Breast Neoplasms
Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization.
Breast Neoplasms
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.
Breast Neoplasms
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Breast Neoplasms
Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Breast Neoplasms
PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.
Breast Neoplasms
PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling.
Breast Neoplasms
Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer.
Breast Neoplasms
Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3?/p53 activation.
Breast Neoplasms
Peptidylarginine Deiminase IV Regulates Breast Cancer Stem Cells via a Novel Tumor Cell-Autonomous Suppressor Role.
Breast Neoplasms
Protein citrullination as a source of cancer neoantigens.
Breast Neoplasms
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells.
Carcinogenesis
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Carcinogenesis
Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Carcinogenesis
Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.
Carcinogenesis
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Carcinogenesis
Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4.
Carcinogenesis
Histone citrullination: a new target for tumors.
Carcinogenesis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Carcinogenesis
Investigating citrullinated proteins in tumour cell lines.
Carcinogenesis
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Carcinogenesis
Long-range enhancer associated with chromatin looping allows AP-1 regulation of the peptidylarginine deiminase 3 gene in differentiated keratinocyte.
Carcinogenesis
PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.
Carcinogenesis
PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling.
Carcinogenesis
PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer.
Carcinogenesis
PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer.
Carcinogenesis
PADI4 and tumourigenesis.
Carcinogenesis
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-? expression levels.
Carcinogenesis
PADI4 Stimulates Esophageal Squamous Cell Carcinoma Tumor Growth and Up-regulates CA9 Expression.
Carcinogenesis
Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer.
Carcinogenesis
Protein-arginine deiminase 2 suppresses proliferation of colon cancer cells through protein citrullination.
Carcinogenesis
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
Carcinoma
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Carcinoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Carcinoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Carcinoma
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Carcinoma
Investigating the pathogenic role of PADI4 in oesophageal cancer.
Carcinoma
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-? expression levels.
Carcinoma
PADI4 Stimulates Esophageal Squamous Cell Carcinoma Tumor Growth and Up-regulates CA9 Expression.
Carcinoma
Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration.
Carcinoma
Role of peptidylarginine deiminase type 4 in gastric cancer.
Carcinoma, Ductal
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Carcinoma, Ductal
Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration.
Carcinoma, Hepatocellular
Decreased PADI4 mRNA Association with Global Hypomethylation in Hepatocellular Carcinoma During HBV Exposure.
Carcinoma, Hepatocellular
Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization.
Carcinoma, Hepatocellular
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Carcinoma, Hepatocellular
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Carcinoma, Hepatocellular
Peptidylarginine deiminase IV promotes the development of chemoresistance through inducing autophagy in hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration.
Carcinoma, Squamous Cell
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Cardiovascular Diseases
Current knowledge into the role of the peptidylarginine deiminase (PAD) enzyme family in cardiovascular disease.
Carotid Stenosis
Peptidylarginine Deiminase 4 as a Possible Biomarker of Plaque Instability in Carotid Artery Stenosis.
Central Nervous System Diseases
Peptidylarginine deiminases and extracellular vesicles: prospective drug targets and biomarkers in central nervous system diseases and repair.
Cholecystitis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Cholera
Stimulation of bovine brain phospholipase C activity by myelin basic protein requires arginyl residues in peptide linkage.
Chondroma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Chronic Periodontitis
Citrullinome of Porphyromonas gingivalis Outer Membrane Vesicles: Confident Identification of Citrullinated Peptides.
Chronic Periodontitis
Periodontal Pathogens in the Etiology of Pancreatic Cancer.
Chronic Periodontitis
[Role of Porphyromonas gingivalis in rheumatoid arthritis and inflammatory spondyloarthropathies].
Colitis
SUPPRESSION OF COLITIS IN MICE BY CL-AMIDINE: A NOVEL PEPTIDYLARGININE DEIMINASE (PAD) INHIBITOR.
Colitis, Ulcerative
Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.
Colitis, Ulcerative
Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population.
Colitis, Ulcerative
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.
Colitis, Ulcerative
The development of N-?-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-?-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.
Colonic Neoplasms
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Colonic Neoplasms
PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer.
Colonic Neoplasms
PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer.
Colonic Neoplasms
Protein-arginine deiminase 2 suppresses proliferation of colon cancer cells through protein citrullination.
Colonic Neoplasms
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest.
Colorectal Neoplasms
Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix.
Colorectal Neoplasms
Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.
Colorectal Neoplasms
The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer.
COVID-19
Putative Roles for Peptidylarginine Deiminases in COVID-19.
Crohn Disease
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Crohn Disease
Genomic modulators of gene expression in human neutrophils.
Cystadenocarcinoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Cystadenocarcinoma, Mucinous
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Cystadenoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Cysts
SUMOylation and deimination of proteins: two epigenetic modifications involved in Giardia encystation.
Demyelinating Diseases
Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.
Demyelinating Diseases
Peptidylarginine deiminase: a candidate factor in demyelinating disease.
Diabetes Mellitus
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Diabetes Mellitus, Type 1
Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes.
Diabetes Mellitus, Type 1
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Diabetes Mellitus, Type 1
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Dysgerminoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Encephalomyelitis
Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice.
Encephalomyelitis, Autoimmune, Experimental
Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice.
Endodermal Sinus Tumor
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Endometrial Hyperplasia
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Endometrial Neoplasms
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Endometrial Neoplasms
PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer.
Endometrial Neoplasms
Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Endotoxemia
Inhibition of peptidylarginine deiminase alleviates LPS-induced pulmonary dysfunction and improves survival in a mouse model of lethal endotoxemia.
Epstein-Barr Virus Infections
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Esophageal Neoplasms
Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Investigating the pathogenic role of PADI4 in oesophageal cancer.
Esophageal Squamous Cell Carcinoma
PADI4 Stimulates Esophageal Squamous Cell Carcinoma Tumor Growth and Up-regulates CA9 Expression.
Felty Syndrome
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps.
Gallstones
Neutrophil Extracellular Traps Initiate Gallstone Formation.
Gastritis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Gingivitis
Evaluation of galectin-3, peptidylarginine deiminase-4 and tumor necrosis factor-? levels in gingival crevicular fluid for periodontal health, gingivitis and stage III grade C periodontitis: A pilot study.
Gingivitis
Impact of chronic gingivitis management on the cytokine and anti-PPAD expressions in juvenile systemic lupus erythematosus: A six-month follow-up.
Glaucoma
Peptidylarginine deiminase type 2 is over expressed in the glaucomatous optic nerve.
Glaucoma
Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis.
Glaucoma, Open-Angle
Peptidylarginine deiminase type 2 is over expressed in the glaucomatous optic nerve.
Glioblastoma
Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines.
Glomerulonephritis
Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps.
Granulosa Cell Tumor
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Graves Disease
Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases.
Heart Diseases
Current knowledge into the role of the peptidylarginine deiminase (PAD) enzyme family in cardiovascular disease.
Heart Diseases
NETosis as a Pathogenic Factor for Heart Failure.
Hemangioma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Hemangioma, Cavernous
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Hepatitis, Chronic
Peptidyl arginine deiminase: A novel immunohistochemical marker for liver fibrosis in patients with chronic hepatitis.
Hydatidiform Mole
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Hyperalgesia
Neutrophil extracellular traps mediate joint hyperalgesia induced by immune inflammation.
Hyperparathyroidism, Secondary
Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease.
Hypersensitivity
Long-range enhancer associated with chromatin looping allows AP-1 regulation of the peptidylarginine deiminase 3 gene in differentiated keratinocyte.
Hypertension
Applicability of Precision Medicine Approaches to Managing Hypertension in Rural Populations.
Infections
Anti-phospholipid Antibodies and Smoking: An Overview.
Infections
Citrullination regulates pluripotency and histone H1 binding to chromatin.
Infections
Inhibition of peptidylarginine deiminase alleviates LPS-induced pulmonary dysfunction and improves survival in a mouse model of lethal endotoxemia.
Infections
Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?
Infections
Mycoplasma and host interaction: In vitro gene expression modulation in Mycoplasma synoviae and infected chicken chondrocytes.
Infections
Neutrophil Extracellular Traps Enhance Early Inflammatory Response in Sendai Virus-Induced Asthma Phenotype.
Infections
Peptidylarginine deiminase from Porphyromonas gingivalis contributes to infection of gingival fibroblasts and induction of prostaglandin E2 -signaling pathway.
Infections
Porphyromonas gingivalis and its LPS differentially regulate the expression of peptidyl arginine deiminases in human chondrocytes.
Infections
Porphyromonas gingivalis Peptidyl Arginine Deiminase Can Modulate Neutrophil Activity via Infection of Human Dental Stem Cells.
Infections
Production of Neutrophil Extracellular Traps Contributes to the Pathogenesis of Francisella tularemia.
Infections
Serum citrullinated histone H3 concentrations differentiate patients with septic verses non-septic shock and correlate with disease severity.
Infections
The activity of bacterial peptidylarginine deiminase is important during formation of dual-species biofilm by periodontal pathogen Porphyromonas gingivalis and opportunistic fungus Candida albicans.
Inflammatory Bowel Diseases
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Invasive Pulmonary Aspergillosis
Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis.
Kidney Neoplasms
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Leiomyoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Leprosy
Genomic modulators of gene expression in human neutrophils.
Leukemia
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Leukemia
Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells.
Leukemia
The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells.
Lipoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Liver Cirrhosis
Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis.
Liver Cirrhosis
Peptidyl arginine deiminase: A novel immunohistochemical marker for liver fibrosis in patients with chronic hepatitis.
Liver Neoplasms
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Low Tension Glaucoma
Peptidylarginine deiminase type 2 is over expressed in the glaucomatous optic nerve.
Lung Diseases
Association of Single Nucleotide Polymorphisms of PADI4 and HLA-DRB1 Alleles with Susceptibility to Rheumatoid Arthritis-Related Lung Diseases.
Lung Diseases, Interstitial
Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Lung Diseases, Interstitial
Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
Lung Injury
Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury.
Lung Neoplasms
Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications.
Lung Neoplasms
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Lung Neoplasms
PADI4?mediated epithelial?mesenchymal transition in lung cancer cells.
Lupus Erythematosus, Systemic
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Lupus Erythematosus, Systemic
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps.
Lupus Erythematosus, Systemic
Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis.
Lupus Erythematosus, Systemic
Impact of chronic gingivitis management on the cytokine and anti-PPAD expressions in juvenile systemic lupus erythematosus: A six-month follow-up.
Lupus Erythematosus, Systemic
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Lupus Erythematosus, Systemic
Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome.
Lupus Erythematosus, Systemic
Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis.
Lupus Erythematosus, Systemic
Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis.
Lupus Erythematosus, Systemic
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Lupus Nephritis
Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice.
Lupus Nephritis
Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis.
Lymphatic Metastasis
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Multiple Myeloma
A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
Multiple Sclerosis
A two-stage case-control association study of PADI2 with schizophrenia.
Multiple Sclerosis
Development of a Selective Inhibitor of Protein Arginine Deiminase 2.
Multiple Sclerosis
Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination.
Multiple Sclerosis
Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.
Multiple Sclerosis
Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.
Multiple Sclerosis
Methylation-dependent PAD2 upregulation in multiple sclerosis peripheral blood.
Multiple Sclerosis
Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.
Multiple Sclerosis
Novel Inhibitors of Protein Arginine Deiminase with Potential Activity in Multiple Sclerosis Animal Model.
Multiple Sclerosis
PADI4 gene in multiple sclerosis: a family-based association study.
Multiple Sclerosis
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Multiple Sclerosis
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Multiple Sclerosis
Peptidylarginine deiminase 4 and citrullination in health and disease.
Multiple Sclerosis
Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis.
Multiple Sclerosis
Role of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation.
Multiple Sclerosis
Targeting citrullination in autoimmunity: insights learned from preclinical mouse models.
Multiple Sclerosis
Vitamin D3 and estradiol alter PAD2 expression and activity levels in C6 glioma cells.
Myocardial Infarction
Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey.
Myocardial Infarction
Histological comparison of arterial thrombi in mice and men and the influence of Cl-amidine on thrombus formation.
Myoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Nasopharyngeal Carcinoma
PADI4, negatively regulated by miR-335-5p, participates in regulating the proliferation, migration, invasion and radiosensitivity of nasopharyngeal carcinoma cells.
Neoplasm Metastasis
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.
Neoplasm Metastasis
Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix.
Neoplasm Metastasis
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.
Neoplasm Metastasis
Endogenous PAD4 in Breast Cancer Cells Mediates Cancer Extracellular Chromatin Network Formation and Promotes Lung Metastasis.
Neoplasm Metastasis
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Neoplasm Metastasis
Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum.
Neoplasm Metastasis
NF-?B and neutrophil extracellular traps cooperate to promote breast cancer progression and metastasis.
Neoplasm Metastasis
PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.
Neoplasm Metastasis
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-? expression levels.
Neoplasm Metastasis
PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition.
Neoplasm Metastasis
PADI4?mediated epithelial?mesenchymal transition in lung cancer cells.
Neoplasm Metastasis
Possible role of Porphyromonas gingivalis in orodigestive cancers.
Neoplasm Metastasis
The lncRNA HOXA11-AS functions as a competing endogenous RNA to regulate PADI2 expression by sponging miR-125a-5p in liver metastasis of colorectal cancer.
Neoplasm Metastasis
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
Neoplasms
Anticancer Peptidylarginine Deiminase (PAD) Inhibitors Regulate the Autophagy Flux and the Mammalian Target of Rapamycin Complex 1 Activity.
Neoplasms
Arginine Citrullination at the C-Terminal Domain Controls RNA Polymerase II Transcription.
Neoplasms
Citrullination of fibronectin alters integrin clustering and focal adhesion stability promoting stromal cell invasion.
Neoplasms
Citrullination of pyruvate kinase M2 by PADI1 and PADI3 regulates glycolysis and cancer cell proliferation.
Neoplasms
Colorectal cancer detection by biomarker quantification in noninvasively collected colorectal mucus: preliminary comparison of 24 protein biomarkers.
Neoplasms
Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix.
Neoplasms
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.
Neoplasms
DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth.
Neoplasms
Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Neoplasms
Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.
Neoplasms
Endogenous PAD4 in Breast Cancer Cells Mediates Cancer Extracellular Chromatin Network Formation and Promotes Lung Metastasis.
Neoplasms
Epitope-Based Chicken-Derived Novel Anti-PAD2 Monoclonal Antibodies Inhibit Citrullination.
Neoplasms
Evaluation of galectin-3, peptidylarginine deiminase-4 and tumor necrosis factor-? levels in gingival crevicular fluid for periodontal health, gingivitis and stage III grade C periodontitis: A pilot study.
Neoplasms
Expression of PADI4 in patients with ankylosing spondylitis and its role in mediating the effects of TNF-? on the proliferation and osteogenic differentiation of human mesenchymal stem cells.
Neoplasms
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors.
Neoplasms
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Neoplasms
Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4.
Neoplasms
Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization.
Neoplasms
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells.
Neoplasms
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.
Neoplasms
Immunologic detection of markers of keratinocyte differentiation. Its use in neoplastic and preneoplastic lesions of skin.
Neoplasms
Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation.
Neoplasms
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Neoplasms
Investigating citrullinated proteins in tumour cell lines.
Neoplasms
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Neoplasms
Investigating the pathogenic role of PADI4 in oesophageal cancer.
Neoplasms
LINC00324 suppresses apoptosis and autophagy in nasopharyngeal carcinoma through upregulation of PAD4 and activation of the PI3K/AKT signaling pathway.
Neoplasms
Molecular alterations in oral cancer using high-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue.
Neoplasms
NF-?B and neutrophil extracellular traps cooperate to promote breast cancer progression and metastasis.
Neoplasms
Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells.
Neoplasms
PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia.
Neoplasms
PADI1 contributes to EMT in PAAD by activating the ERK1/2-p38 signaling pathway.
Neoplasms
PADI2 gene confers susceptibility to breast cancer and plays tumorigenic role via ACSL4, BINC3 and CA9 signaling.
Neoplasms
PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer.
Neoplasms
PADI2-mediated citrullination promotes prostate cancer progression.
Neoplasms
PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer.
Neoplasms
PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer.
Neoplasms
PADI4 and tumourigenesis.
Neoplasms
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-? expression levels.
Neoplasms
PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition.
Neoplasms
PADI4 Stimulates Esophageal Squamous Cell Carcinoma Tumor Growth and Up-regulates CA9 Expression.
Neoplasms
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.
Neoplasms
Peptidyl Arginine Deiminase 2 (PADI2)-Mediated Arginine Citrullination Modulates Transcription in Cancer.
Neoplasms
Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer.
Neoplasms
Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation.
Neoplasms
Peptidylarginine deiminase 4 contributes to tumor necrosis factor alpha induced inflammatory arthritis.
Neoplasms
Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.
Neoplasms
Peptidylarginine Deiminase IV Regulates Breast Cancer Stem Cells via a Novel Tumor Cell-Autonomous Suppressor Role.
Neoplasms
Peptidylarginine deiminases and extracellular vesicles: prospective drug targets and biomarkers in central nervous system diseases and repair.
Neoplasms
Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.
Neoplasms
Possible role of Porphyromonas gingivalis in orodigestive cancers.
Neoplasms
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis.
Neoplasms
Protein arginine deiminase 4: a target for an epigenetic cancer therapy.
Neoplasms
Protein citrullination as a source of cancer neoantigens.
Neoplasms
Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Neoplasms
Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.
Neoplasms
Regulation of Protein Citrullination through p53/PADI4 Network in DNA Damage Response.
Neoplasms
Rheumatoid arthritis susceptibility genes: An overview.
Neoplasms
Role of citrullination modification catalyzed by peptidylarginine deiminase 4 in gene transcriptional regulation.
Neoplasms
Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration.
Neoplasms
Role of peptidylarginine deiminase type 4 in gastric cancer.
Neoplasms
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
Neoplasms
Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer.
Neoplasms
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.
Neoplasms
The development of N-?-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-?-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.
Neoplasms
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
Neoplasms
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation.
Neoplasms
[Effect of PADI4 on the Expression of Inflammatory Cytokines During NB4 Cells Differentiation].
Neoplasms, Germ Cell and Embryonal
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Neoplasms, Squamous Cell
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Nephritis
Lupus and proliferative nephritis are PAD4 independent in murine models.
Neurilemmoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Neurodegenerative Diseases
Age-related reduction in retinal deimination levels in the F344BN rat.
Neurodegenerative Diseases
Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay.
Neurodegenerative Diseases
Peptidylarginine deiminase modulates the physiological roles of enolase via citrullination: links between altered multifunction of enolase and neurodegenerative diseases.
Neurofibroma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Osteoarthritis
Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Osteoarthritis
Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis.
Osteoarthritis
Expression of PADI4 in patients with ankylosing spondylitis and its role in mediating the effects of TNF-? on the proliferation and osteogenic differentiation of human mesenchymal stem cells.
Osteoarthritis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Osteoarthritis
PADI2 is significantly associated with rheumatoid arthritis.
Osteoarthritis
Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis.
Osteoarthritis
The expression of PADI4 in synovium of rheumatoid arthritis.
Osteoarthritis
Tumour necrosis factor alpha promotes secretion of 14-3-3? by inducing necroptosis in macrophages.
Osteomalacia
Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease.
Osteosarcoma
Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4.
Osteosarcoma
PADI4 modulates the invasion and migration of osteosarcoma cells by down-regulation of epithelial-mesenchymal transition.
Ovarian Neoplasms
Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Ovarian Neoplasms
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Ovarian Neoplasms
The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.
Pancreatic Neoplasms
DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth.
Pancreatic Neoplasms
Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.
Pancreatitis
Different Types of Periampullary Duodenal Diverticula Are Associated with Occurrence and Recurrence of Bile Duct Stones: A Case-Control Study from a Chinese Center.
Pancreatitis
Targeting peptidylarginine deiminase reduces neutrophil extracellular trap formation and tissue injury in severe acute pancreatitis.
Periodontal Diseases
Gingival crevicular fluid semaphorin 4D and peptidylarginine deiminase-2 levels in periodontal health and disease.
Periodontal Diseases
Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis.
Periodontal Diseases
Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis.
Periodontal Diseases
Rheumatoid arthritis and periodontal disease.
Periodontal Diseases
Serum antibody levels against Porphyromonas gingivalis in patients with and without rheumatoid arthritis - a systematic review and meta-analysis.
Periodontal Diseases
The role of anti-cyclic citrullinated peptide antibody in periodontal disease.
Periodontitis
Aggravation of collagen-induced arthritis by orally administered Porphyromonas gingivalis through modulation of the gut microbiota and gut immune system.
Periodontitis
Anti-phospholipid Antibodies and Smoking: An Overview.
Periodontitis
Citrullination in the periodontium-a possible link between periodontitis and rheumatoid arthritis.
Periodontitis
Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis.
Periodontitis
Effects by periodontitis on pristane-induced arthritis in rats.
Periodontitis
Evaluation of galectin-3, peptidylarginine deiminase-4 and tumor necrosis factor-? levels in gingival crevicular fluid for periodontal health, gingivitis and stage III grade C periodontitis: A pilot study.
Periodontitis
Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.
Periodontitis
Increased citrullination and expression of peptidylarginine deiminases independently of P. gingivalis and A. actinomycetemcomitans in gingival tissue of patients with periodontitis.
Periodontitis
Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe?
Periodontitis
Oral Biofilms from Symbiotic to Pathogenic Interactions and Associated Disease -Connection of Periodontitis and Rheumatic Arthritis by Peptidylarginine Deiminase.
Periodontitis
Rheumatoid arthritis and periodontal disease.
Peripheral Arterial Disease
Effect of Peptidylarginine Deiminase 4 on Endothelial Progenitor Cell Function in Peripheral Arterial Disease.
Pneumonia
Historical introgression from wild relatives enhanced climatic adaptation and resistance to pneumonia in sheep.
Pneumonia
Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation.
Prion Diseases
Peptidylarginine deiminase and protein citrullination in prion diseases: Strong evidence of neurodegeneration.
protein-arginine deiminase deficiency
Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury.
protein-arginine deiminase deficiency
Peptidylarginine deiminase type 4 deficiency reduced arthritis severity in a glucose-6-phosphate isomerase-induced arthritis model.
Proteinuria
Peptidylarginine Deiminase 4 Promotes the Renal Infiltration of Neutrophils and Exacerbates the TLR7 Agonist-Induced Lupus Mice.
Psoriasis
Unraveling the genetics of complex diseases: Susceptibility genes for rheumatoid arthritis and psoriasis.
Pulmonary Disease, Chronic Obstructive
Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis.
Pulmonary Disease, Chronic Obstructive
Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities.
Pulmonary Fibrosis
PAD4 Deficiency Improves Bleomycin-induced Neutrophil Extracellular Traps and Fibrosis in Mouse Lung.
Pyelonephritis
TcpC inhibits neutrophil extracellular trap formation by enhancing ubiquitination mediated degradation of peptidylarginine deiminase 4.
Rheumatic Diseases
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis.
Rheumatic Diseases
Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism.
Rheumatic Diseases
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Rheumatic Diseases
Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis.
Rheumatic Diseases
[The significance of serum peptidylarginine deiminase 4 in rheumatoid arthritis.]
Rheumatic Fever
Oral Biofilms from Symbiotic to Pathogenic Interactions and Associated Disease -Connection of Periodontitis and Rheumatic Arthritis by Peptidylarginine Deiminase.
Sarcoma
Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis.
Sepsis
Cl-Amidine Improves Survival and Attenuates Kidney Injury in a Rabbit Model of Endotoxic Shock.
Sepsis
Neutrophil extracellular traps (NETs) exacerbate severity of infant sepsis.
Sepsis
Peptidylarginine deiminase 2 has potential as both a biomarker and therapeutic target of sepsis.
Sepsis
Role of Peptidylarginine Deiminase 4 in Neutrophil Extracellular Trap Formation and Host Defense during Klebsiella pneumoniae-Induced Pneumonia-Derived Sepsis.
Shock, Septic
Citrullinated histone H3: a novel target for the treatment of sepsis.
Shock, Septic
Evaluation of peptidylarginine deiminase 4 and PADI4 polymorphisms in sepsis-induced acute kidney injury.
Shock, Septic
Neutrophil extracellular traps impair intestinal barrier functions in sepsis by regulating TLR9-mediated endoplasmic reticulum stress pathway.
Shock, Septic
Peptidylarginine deiminase 4 concentration, but not PADI4 polymorphisms, is associated with ICU mortality in septic shock patients.
Shock, Septic
Protective effect of Cl-amidine against CLP-induced lethal septic shock in mice.
Skin Neoplasms
Immunohistochemical demonstration of peptidylarginine deiminase in human sweat glands.
Spondylitis, Ankylosing
Expression of PADI4 in patients with ankylosing spondylitis and its role in mediating the effects of TNF-? on the proliferation and osteogenic differentiation of human mesenchymal stem cells.
Spondylitis, Ankylosing
PADI4 Gene Polymorphism is not Associated with Ankylosing Spondylitis in Chinese Han Population.
Spondylitis, Ankylosing
The expression of PADI4 in synovium of rheumatoid arthritis.
Stomach Neoplasms
A Novel Citrullinated Modification of Histone 3 and Its Regulatory Mechanisms Related to IPO-38 Antibody-Labeled Protein.
Stomach Neoplasms
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Stomach Neoplasms
Role of peptidylarginine deiminase type 4 in gastric cancer.
Stroke
Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey.
Stroke
[Effect of neutrophil extracellular traps on ischemic stroke and intervention of traditional Chinese medicine].
Synovitis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Teratoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Teratoma
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Thecoma
Expression of peptidylarginine deiminase type 4 in ovarian tumors.
Thrombosis
Effect of Peptidylarginine Deiminase 4 on Endothelial Progenitor Cell Function in Peripheral Arterial Disease.
Thrombosis
Histological comparison of arterial thrombi in mice and men and the influence of Cl-amidine on thrombus formation.
Thrombosis
Neutrophil accumulation and NET release contribute to thrombosis in HIT.
Thrombosis
Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis.
Thrombosis
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice.
Thrombosis
Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury.
Thrombosis
Role of HMGB1 in the Interplay between NETosis and Thrombosis in Ischemic Stroke: A Review.
Thrombosis
Thrombosis: tangled up in NETs.
Thyroid Cancer, Papillary
Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.
Thyroiditis
Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases.
Tuberculosis
Heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis in Koreans.
Tuberculosis
Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?
Urinary Bladder Neoplasms
Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer.
Uterine Cervicitis
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
Vascular Diseases
Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.
Vasculitis
Significance of serum peptidylarginine deiminase type 4 in ANCA-associated vasculitis.
Venous Thrombosis
Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis.
Venous Thrombosis
Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice.
Vitamin D Deficiency
Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease.
Wound Infection
Long-term follow-up of superior gluteal artery perforator flap closure of large myelomeningoceles.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
66.3
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 3
33.6
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 3
7.5
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 3
0.11 - 0.18
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.32 - 0.36
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.3 - 0.95
Ac-Ala-Gly-Arg-Gly-Lys
0.69 - 0.8
Ac-Ser-Ala-Arg-Gly-Lys
0.44 - 1.75
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
0.58
Ac-Ser-Gly-Arg-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.15 - 1.07
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
0.37
Ac-Ser-Gly-Arg-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.86
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.16 - 0.58
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
0.17 - 0.34
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
0.43 - 0.66
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
0.15 - 0.59
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
1.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.22 - 1.95
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
0.48 - 2.16
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
0.21 - 0.64
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
0.48 - 3.27
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
0.91
acetyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 1
1.19 - 3.73
acetyl-L-Arg methyl ester
0.15 - 0.91
benzoyl-Arg-ethyl ester
0.63 - 1.97
benzoyl-Arg-methyl ester
0.16 - 1.23
benzoyl-Arg-NH2
0.38 - 1.49
benzoyl-L-Arg
0.35 - 0.5
benzoyl-L-Arg ethyl ester
0.41
benzoyl-L-arginine
37°C
0.25
benzoyl-L-arginine amide
37°C
1.36
benzoyl-L-arginine ethyl ester
37°C
1.66
benzoyl-L-arginine methyl ester
37°C
0.013 - 0.055
fibrinogen
-
0.001 - 0.064
filaggrin
-
0.14
histone H4-L-arginine
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.325
KDRNW
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.45
LDRGE
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.27
MWRHV
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.16 - 17.5
N-alpha-benzoyl-L-arginine amide
0.1 - 30
N-alpha-benzoyl-L-arginine ethyl ester
0.37 - 10.8
N-alpha-benzoyl-L-arginine methyl ester
0.44 - 1.7
Nalpha-benzoyl L-arginine ethyl ester
0.41 - 1.6
Nalpha-benzoyl-L-arginine
0.25 - 0.48
Nalpha-benzoyl-L-arginine amide
0.27 - 2.77
Nalpha-benzoyl-L-arginine ethyl ester
0.24 - 1.66
Nalpha-benzoyl-L-arginine methyl ester
0.372
TKQTARKSTGGK
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
1.63 - 5.61
tosyl-Arg-ethyl ester
0.575
TSTGGRQGSHH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.12
WSRYH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.345
WTRGE
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.187
YWRDH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.088 - 0.35
[histone H4]-L-Arg
0.11
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.18
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.32
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.36
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.3
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.95
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.69
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.8
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.44
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.75
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.15
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.59
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.07
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.16
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.58
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.17
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.34
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.43
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.66
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.15
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.2
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.59
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.22
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.52
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.95
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.48
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.16
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.21
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.42
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.64
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.48
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.86
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.27
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.19
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
3.73
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 2
0.15
benzoyl-Arg-ethyl ester
-
pH 7.6, 37°C, hPADI2 expressed by baculovirus
0.73
benzoyl-Arg-ethyl ester
-
pH 7.6, 37°C, hPADI2 expressed in Escherichia coli
0.91
benzoyl-Arg-ethyl ester
-
pH 7.6, 37°C, hPADI4 expressed in Escherichia coli
0.63
benzoyl-Arg-methyl ester
-
pH 7.6, 37°C, hPADI4 expressed in Escherichia coli
0.77
benzoyl-Arg-methyl ester
-
pH 7.6, 37°C, hPADI2 expressed by baculovirus
1.97
benzoyl-Arg-methyl ester
-
pH 7.6, 37°C, hPADI2 expressed in Escherichia coli
0.16
benzoyl-Arg-NH2
-
pH 7.6, 37°C, hPADI4 expressed in Escherichia coli
1.01
benzoyl-Arg-NH2
-
pH 7.6, 37°C, hPADI2 expressed in Escherichia coli
1.23
benzoyl-Arg-NH2
-
pH 7.6, 37°C, hPADI2 expressed by baculovirus
0.38
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 1
1.49
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 2
0.35
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
0.5
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 2
0.013
fibrinogen
-
hPADI2
-
0.055
fibrinogen
-
hPADI4
-
0.001
filaggrin
-
hPADI2
-
0.064
filaggrin
-
hPADI4
-
0.16
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.25
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
13.9
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
17.5
N-alpha-benzoyl-L-arginine amide
-
mutant PAD3 enzyme G374R, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant F221A/F222A, pH 7.6, 37°C
0.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469T, pH 7.5, 25°C
0.1
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme F221A/F222A
0.12
N-alpha-benzoyl-L-arginine ethyl ester
mutant D123N, pH 7.6, 37°C
0.12
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D123N
0.14
N-alpha-benzoyl-L-arginine ethyl ester
mutant D125A, pH 7.6, 37°C
0.14
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D125A
0.16
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.6, 37°C
0.16
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, wild-type enzyme
0.19
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.25
N-alpha-benzoyl-L-arginine ethyl ester
mutant D169A, pH 7.6, 37°C
0.25
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D169A
0.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548K, pH 7.5, 25°C
0.33
N-alpha-benzoyl-L-arginine ethyl ester
mutant D166A, pH 7.6, 37°C
0.33
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D166A
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant C434A, pH 7.5, 25°C
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant D465A, pH 7.5, 25°C
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant F576A, pH 7.5, 25°C
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279A, pH 7.5, 25°C
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279I, pH 7.5, 25°C
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374Q, pH 7.5, 25°C
0.5
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.5, 25°C
0.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6D, pH 7.5, 25°C
0.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6I, pH 7.5, 25°C
0.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283I, pH 7.5, 25°C
0.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284I, pH 7.5, 25°C
0.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant D389A, pH 7.6, 37°C
0.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6A, pH 7.5, 25°C
0.6
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D389A
0.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant F541A, pH 7.5, 25°C
0.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374A, pH 7.5, 25°C
0.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant R639A, pH 7.5, 25°C
0.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283A, pH 7.5, 25°C
0.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant F285A, pH 7.5, 25°C
0.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283T, pH 7.5, 25°C
0.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284D, pH 7.5, 25°C
1
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469L, pH 7.5, 25°C
1.36
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548F, pH 7.5, 25°C
1.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284A, pH 7.5, 25°C
1.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant R441A, pH 7.5, 25°C
1.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279D, pH 7.5, 25°C
2.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372Q, pH 7.5, 25°C
2.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant D177A, pH 7.6, 37°C
2.4
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D177A
3.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant Y435A, pH 7.5, 25°C
3.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant E352A, pH 7.6, 37°C
3.4
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E352A
3.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372A, pH 7.5, 25°C
4.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant R347A, pH 7.6, 37°C
4.4
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme R347
5
N-alpha-benzoyl-L-arginine ethyl ester
mutant D370A, pH 7.6, 37°C
5
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D370A
5.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469A, pH 7.5, 25°C
6.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant Q350A, pH 7.6, 37°C
6.3
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme Q350A
8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D374A, pH 7.6, 37°C
8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D374A
13
N-alpha-benzoyl-L-arginine ethyl ester
mutant E412A, pH 7.6, 37°C
13
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E412A
30
N-alpha-benzoyl-L-arginine ethyl ester
mutant R373A, pH 7.6, 37°C
30
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme W373A
0.37
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.66
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
10.8
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.44
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant S55G
0.45
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484K
0.45
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484Q
0.48
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205Q
0.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156K
0.58
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, wild-type
0.69
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639K
0.72
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419K
0.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A112G
0.86
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123K
0.87
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419Q
0.89
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609Q
1.2
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374Q
1.2
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639Q
1.35
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A82V
1.4
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123Q
1.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205K
1.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609K
1.6
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156Q
1.7
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374K
0.41
Nalpha-benzoyl-L-arginine
at pH 7.5 and 37°C
1.6
Nalpha-benzoyl-L-arginine
at pH 7.6 and 37°C
0.25
Nalpha-benzoyl-L-arginine amide
at pH 7.5 and 37°C
0.48
Nalpha-benzoyl-L-arginine amide
at pH 7.6 and 37°C
0.27
Nalpha-benzoyl-L-arginine ethyl ester
at pH 7.6 and 37°C
0.31
Nalpha-benzoyl-L-arginine ethyl ester
-
wild-type, pH 7.4, 25°C
0.35
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D273A/R544A, pH 7.4, 25°C
0.36
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547A, pH 7.4, 25°C
0.36
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y237A, pH 7.4, 25°C
0.38
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y237A/E281A, pH 7.4, 25°C
0.4
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8A/D547A, pH 7.4, 25°C
0.45
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant E281A, pH 7.4, 25°C
0.47
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8A, pH 7.4, 25°C
0.47
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8H, pH 7.4, 25°C
0.5
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8K, pH 7.4, 25°C
0.6
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8Q , pH 7.4, 25°C
0.72
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547E, pH 7.4, 25°C
0.86
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547N, pH 7.4, 25°C
1.06
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8E, pH 7.4, 25°C
1.36
Nalpha-benzoyl-L-arginine ethyl ester
at pH 7.5 and 37°C
1.36
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8L, pH 7.4, 25°C
2.33
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y435A, pH 7.4, 25°C
2.73
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y435N, pH 7.4, 25°C
2.77
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8E/D547E, pH 7.4, 25°C
0.24
Nalpha-benzoyl-L-arginine methyl ester
at pH 7.6 and 37°C
1.66
Nalpha-benzoyl-L-arginine methyl ester
at pH 7.5 and 37°C
1.63
tosyl-Arg-ethyl ester
-
pH 7.6, 37°C, hPADI2 expressed by baculovirus
5.61
tosyl-Arg-ethyl ester
-
pH 7.6, 37°C, hPADI2 expressed in Escherichia coli
0.088
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374K
0.094
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639Q
0.1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123Q
0.11
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156Q
0.14
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419K
0.15
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374Q
0.15
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639K
0.17
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A112G
0.18
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156K
0.18
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R609Q
0.2
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant S55G
0.21
[histone H4]-L-Arg
-
37°C, pH 7.6, wild-type
0.22
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419Q
0.24
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123K
0.26
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484K
0.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484Q
0.35
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A82V
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.93
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 3
0.79
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 3
1.73
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 3
0.45
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.48
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.21 - 0.59
Ac-Ala-Gly-Arg-Gly-Lys
0.62 - 1.13
Ac-Ser-Ala-Arg-Gly-Lys
1.46
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.98
Ac-Ser-Gly-Arg-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.57 - 1.08
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
0.93
Ac-Ser-Gly-Arg-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.83
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.75 - 2.53
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
0.77
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.87
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.08 - 2.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.64 - 4.92
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
1.83
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.31 - 3.39
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
0.34 - 0.56
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
13.68
acetyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 1
0.057 - 11.28
acetyl-L-Arg methyl ester
0.52 - 14.43
benzoyl-L-Arg
0.057 - 15.24
benzoyl-L-Arg ethyl ester
3.35
benzoyl-L-arginine
37°C
2.76 - 6
benzoyl-L-arginine amide
5.94
benzoyl-L-arginine ethyl ester
37°C
5.57
benzoyl-L-arginine methyl ester
37°C
2
KDRNW
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
2.9
LDRGE
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
2
MWRHV
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
1.85 - 3.57
N-alpha-benzoyl-L-arginine amide
0.03 - 11.7
N-alpha-benzoyl-L-arginine ethyl ester
1.26 - 5.57
N-alpha-benzoyl-L-arginine methyl ester
0.55 - 3.8
Nalpha-benzoyl L-arginine ethyl ester
0.63
Nalpha-benzoyl-L-arginine
at pH 7.6 and 37°C
0.32
Nalpha-benzoyl-L-arginine amide
at pH 7.6 and 37°C
3.2 - 13.9
Nalpha-benzoyl-L-arginine ethyl ester
0.43
Nalpha-benzoyl-L-arginine methyl ester
at pH 7.6 and 37°C
0.7
TKQTARKSTGGK
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
1.3
TSTGGRQGSHH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
1.8
WSRYH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
3.3
WTRGE
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
2.3
YWRDH
-
in 60 mM MOPS buffer, pH 7.5 and 10 mM CaCl2, at 37°C
0.49 - 2.1
[histone H4]-L-Arg
0.21
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.59
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.62
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.13
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.57
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.08
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.75
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.53
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.08
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.6
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.64
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.29
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.92
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.31
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.81
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.39
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.34
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.56
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.057 - 0.65
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
6.22
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 2
11.28
acetyl-L-Arg methyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
0.52
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 1
3.15
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 2
14.43
benzoyl-L-Arg
pH 7.6, 55°C, peptidylarginine deiminase 1
0.057 - 0.65
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
0.55
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 2
11.31
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 1
15.24
benzoyl-L-Arg ethyl ester
pH 7.6, 55°C, peptidylarginine deiminase 2
2.76
benzoyl-L-arginine amide
37°C
3 - 6
benzoyl-L-arginine amide
37°C
1.85
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.1
N-alpha-benzoyl-L-arginine amide
-
mutant PAD3 enzyme G374R, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.76
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.57
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.03
N-alpha-benzoyl-L-arginine ethyl ester
mutant Q350A, pH 7.6, 37°C
0.03
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme Q350A
0.04
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469T, pH 7.5, 25°C
0.07
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372A, pH 7.5, 25°C
0.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant E412A, pH 7.6, 37°C
0.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469L, pH 7.5, 25°C
0.1
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E412A
0.12
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372Q, pH 7.5, 25°C
0.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant R373A, pH 7.6, 37°C
0.2
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme W373A
0.25
N-alpha-benzoyl-L-arginine ethyl ester
mutant E352A, pH 7.6, 37°C
0.25
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E352A
0.27
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.35
N-alpha-benzoyl-L-arginine ethyl ester
mutant D166A, pH 7.6, 37°C
0.35
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D166A
0.51
N-alpha-benzoyl-L-arginine ethyl ester
mutant D389A, pH 7.6, 37°C
0.51
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D389A
0.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant D370A, pH 7.6, 37°C
0.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548K, pH 7.5, 25°C
0.6
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D370A
0.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D123N, pH 7.6, 37°C
0.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D125A, pH 7.6, 37°C
0.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469A, pH 7.5, 25°C
0.8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D123N
0.8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D125A
1.53
N-alpha-benzoyl-L-arginine ethyl ester
mutant R347A, pH 7.6, 37°C
1.53
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme R347
1.55
N-alpha-benzoyl-L-arginine ethyl ester
mutant D374A, pH 7.6, 37°C
1.55
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D374A
1.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D169A, pH 7.6, 37°C
1.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant F221A/F222A, pH 7.6, 37°C
1.8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D169A
1.8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme F221A/F222A
2.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant R441A, pH 7.5, 25°C
2.65
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, wild-type enzyme
2.65
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.6, 37°C
2.65
N-alpha-benzoyl-L-arginine ethyl ester
mutant D177A, pH 7.6, 37°C
2.65
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D177A
2.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant Y435A, pH 7.5, 25°C
2.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284D, pH 7.5, 25°C
3.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant D465A, pH 7.5, 25°C
3.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279D, pH 7.5, 25°C
3.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374Q, pH 7.5, 25°C
4.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6D, pH 7.5, 25°C
5
N-alpha-benzoyl-L-arginine ethyl ester
mutant R639A, pH 7.5, 25°C
5.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279A, pH 7.5, 25°C
5.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283T, pH 7.5, 25°C
5.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284A, pH 7.5, 25°C
5.94
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
6.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548F, pH 7.5, 25°C
6.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant F285A, pH 7.5, 25°C
7.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6A, pH 7.5, 25°C
7.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant F541A, pH 7.5, 25°C
7.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374A, pH 7.5, 25°C
8
N-alpha-benzoyl-L-arginine ethyl ester
mutant C434A, pH 7.5, 25°C
8
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283A, pH 7.5, 25°C
9.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283I, pH 7.5, 25°C
9.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant F576A, pH 7.5, 25°C
10.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6I, pH 7.5, 25°C
10.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284I, pH 7.5, 25°C
11.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279I, pH 7.5, 25°C
11.7
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.5, 25°C
1.26
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.85
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
5.57
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.55
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419Q
0.76
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156K
1.1
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484K
1.2
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205Q
1.2
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484Q
1.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A112G
1.6
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639Q
1.9
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609Q
1.9
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639K
2.3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123Q
2.3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374Q
2.6
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609K
2.7
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A82V
2.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant S55G
2.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, wild-type
3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374K
3.1
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419K
3.6
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156Q
3.7
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123K
3.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205K
3.2
Nalpha-benzoyl-L-arginine ethyl ester
at pH 7.6 and 37°C
3.3
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8E/D547E, pH 7.4, 25°C
4
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y435N, pH 7.4, 25°C
5.3
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8L, pH 7.4, 25°C
5.9
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y435A, pH 7.4, 25°C
7.3
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8E, pH 7.4, 25°C
8.9
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547E, pH 7.4, 25°C
10.08
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8K, pH 7.4, 25°C
10.7
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8A/D547A, pH 7.4, 25°C
11.6
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547A, pH 7.4, 25°C
12.1
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant E281A, pH 7.4, 25°C
12.2
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D547N, pH 7.4, 25°C
12.2
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8A, pH 7.4, 25°C
12.2
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8Q , pH 7.4, 25°C
13.2
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y237A/E281A, pH 7.4, 25°C
13.3
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant R8H, pH 7.4, 25°C
13.4
Nalpha-benzoyl-L-arginine ethyl ester
-
wild-type, pH 7.4, 25°C
13.5
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant D273A/R544A, pH 7.4, 25°C
13.9
Nalpha-benzoyl-L-arginine ethyl ester
-
mutant Y237A, pH 7.4, 25°C
0.49
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374K
0.77
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374Q
0.78
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639Q
0.79
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156Q
0.9
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123Q
1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A112G
1.1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant S55G
1.2
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419Q
1.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419K
1.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639K
1.4
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A82V
1.4
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156K
1.5
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R609Q
1.6
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484K
1.6
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484Q
1.7
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123K
2.1
[histone H4]-L-Arg
-
37°C, pH 7.6, wild-type
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.2 - 5.7
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.001 - 1.4
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.22 - 3.5
Ac-Ala-Gly-Arg-Gly-Lys
0.9 - 5.8
Ac-Ser-Ala-Arg-Gly-Lys
0.01 - 3.3
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
0.08 - 6.6
Ac-Ser-Gly-Arg-Ala-Lys
1.8 - 3.9
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
0.05 - 16
Ac-Ser-Gly-Arg-Gly-Ala
0.001 - 3.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
2 - 4.6
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
1 - 19
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
0.7 - 14
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
0.5 - 3.9
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
0.3 - 2.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val
2.5 - 4.4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
0.001 - 3.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
0.7 - 5.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
0.4 - 1.2
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
0.7 - 9
histone H4-L-arginine
0.13 - 120000
N-alpha-benzoyl-L-arginine amide
0.005 - 13800
N-alpha-benzoyl-L-arginine ethyl ester
0.12 - 10.4
N-alpha-benzoyl-L-arginine methyl ester
0.63 - 6.4
Nalpha-benzoyl L-arginine ethyl ester
0.39
Nalpha-benzoyl-L-arginine
at pH 7.6 and 37°C
0.68
Nalpha-benzoyl-L-arginine amide
at pH 7.6 and 37°C
11.7
Nalpha-benzoyl-L-arginine ethyl ester
at pH 7.6 and 37°C
1.8
Nalpha-benzoyl-L-arginine methyl ester
at pH 7.6 and 37°C
0.0031 - 10
[histone H4]-L-Arg
0.2
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.2
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
5.7
2-acetyl-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.001
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
kcat_Km value less than 0.001 mM-1*sec-1, isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.4
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.4
3-acetyl-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.22
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.5
Ac-Ala-Gly-Arg-Gly-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.9
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.4
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
5.8
Ac-Ser-Ala-Arg-Gly-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.01
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.58
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.3
Ac-Ser-Gly-Ala-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.08
Ac-Ser-Gly-Arg-Ala-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.7
Ac-Ser-Gly-Arg-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
6.6
Ac-Ser-Gly-Arg-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.8
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.4
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.9
Ac-Ser-Gly-Arg-Gly-acetyl-Lys-Gly-Gly-acetyl-Lys-Gly-Leu-Gly-acetyl-Lys-Gly-Gly-Ala-acetyl-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.05
Ac-Ser-Gly-Arg-Gly-Ala
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.5
Ac-Ser-Gly-Arg-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
16
Ac-Ser-Gly-Arg-Gly-Ala
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.001
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
-
kcat_Km value less than 0.001 mM-1*sec-1, isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.085
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.6
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
19
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
14
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Ala-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.5
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.1
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.9
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.6
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Ala-His-Arg-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
2.5
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.001
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
kcat_Km value less than 0.001 mM-1*sec-1, isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Ala-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.7
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
5.3
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Arg-His-Arg-Lys-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.4
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.5
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.2
Ac-Ser-Gly-Arg-Gly-Lys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-Ala-Lys-Lys-His-Lys-Ala-Val
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.7
histone H4-L-arginine
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.3
histone H4-L-arginine
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
9
histone H4-L-arginine
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.13
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
11
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
22
N-alpha-benzoyl-L-arginine amide
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
120000
N-alpha-benzoyl-L-arginine amide
-
mutant PAD3 enzyme G374R, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.005
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme Q350A
0.007
N-alpha-benzoyl-L-arginine ethyl ester
mutant E412A, pH 7.6, 37°C
0.007
N-alpha-benzoyl-L-arginine ethyl ester
mutant R373A, pH 7.6, 37°C
0.007
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E412A
0.007
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme W373A
0.02
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372A, pH 7.5, 25°C
0.025
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.05
N-alpha-benzoyl-L-arginine ethyl ester
mutant Q350A, pH 7.6, 37°C
0.05
N-alpha-benzoyl-L-arginine ethyl ester
mutant R372Q, pH 7.5, 25°C
0.075
N-alpha-benzoyl-L-arginine ethyl ester
mutant E352A, pH 7.6, 37°C
0.075
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme E352A
0.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469L, pH 7.5, 25°C
0.115
N-alpha-benzoyl-L-arginine ethyl ester
mutant D370A, pH 7.6, 37°C
0.115
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D370A
0.15
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469A, pH 7.5, 25°C
0.195
N-alpha-benzoyl-L-arginine ethyl ester
mutant D374A, pH 7.6, 37°C
0.195
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D374A
0.35
N-alpha-benzoyl-L-arginine ethyl ester
mutant R347A, pH 7.6, 37°C
0.35
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme R347
0.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant V469T, pH 7.5, 25°C
0.845
N-alpha-benzoyl-L-arginine ethyl ester
mutant D389A, pH 7.6, 37°C
0.845
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D389A
0.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant Y435A, pH 7.5, 25°C
1.065
N-alpha-benzoyl-L-arginine ethyl ester
mutant D166A, pH 7.6, 37°C
1.065
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D166A
1.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant D177A, pH 7.6, 37°C
1.1
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D177A
1.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant R441A, pH 7.5, 25°C
1.5
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
1.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279D, pH 7.5, 25°C
2
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548K, pH 7.5, 25°C
3.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284D, pH 7.5, 25°C
3.7
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284A, pH 7.5, 25°C
4.4
N-alpha-benzoyl-L-arginine ethyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
4.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant W548F, pH 7.5, 25°C
6
N-alpha-benzoyl-L-arginine ethyl ester
mutant D125A, pH 7.6, 37°C
6
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D125A
6.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283T, pH 7.5, 25°C
6.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D123N, pH 7.6, 37°C
6.8
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D123N
7.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant R639A, pH 7.5, 25°C
7.9
N-alpha-benzoyl-L-arginine ethyl ester
mutant D169A, pH 7.6, 37°C
7.9
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme D169A
8.6
N-alpha-benzoyl-L-arginine ethyl ester
mutant F285A, pH 7.5, 25°C
8.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant D465A, pH 7.5, 25°C
9
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6D, pH 7.5, 25°C
9.3
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374Q, pH 7.5, 25°C
11
N-alpha-benzoyl-L-arginine ethyl ester
mutant F541A, pH 7.5, 25°C
11.1
N-alpha-benzoyl-L-arginine ethyl ester
mutant R374A, pH 7.5, 25°C
11.4
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283A, pH 7.5, 25°C
12.2
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6A, pH 7.5, 25°C
13.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279A, pH 7.5, 25°C
16.5
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, wild-type enzyme
16.5
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.6, 37°C
18
N-alpha-benzoyl-L-arginine ethyl ester
mutant F221A/F222A, pH 7.6, 37°C
18
N-alpha-benzoyl-L-arginine ethyl ester
pH 7.6, 37°C, mutant enzyme F221A/F222A
19
N-alpha-benzoyl-L-arginine ethyl ester
mutant V283I, pH 7.5, 25°C
20
N-alpha-benzoyl-L-arginine ethyl ester
mutant C434A, pH 7.5, 25°C
21.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant L6I, pH 7.5, 25°C
21.8
N-alpha-benzoyl-L-arginine ethyl ester
mutant V284I, pH 7.5, 25°C
23.4
N-alpha-benzoyl-L-arginine ethyl ester
wild-type, pH 7.5, 25°C
24.5
N-alpha-benzoyl-L-arginine ethyl ester
mutant F576A, pH 7.5, 25°C
28
N-alpha-benzoyl-L-arginine ethyl ester
mutant L279I, pH 7.5, 25°C
13800
N-alpha-benzoyl-L-arginine ethyl ester
-
mutant PAD3 enzyme G374R, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.12
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD3, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
3.3
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD4, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
10.4
N-alpha-benzoyl-L-arginine methyl ester
-
isozyme PAD1, at 37°C, 10 mM CaCl2, 50 mM NaCl, 100 mM Tris-HCl, pH 7.6, 2 mM dithiothreitol
0.63
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419Q
1.3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639Q
1.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156K
1.6
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123Q
1.7
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609K
1.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374K
1.9
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A112G
1.9
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R374Q
2.1
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant A82V
2.1
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R609Q
2.2
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R156Q
2.4
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484K
2.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205K
2.5
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R205Q
2.7
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R484Q
2.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R639K
4.3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R123K
4.3
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant R419K
4.8
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, wild-type
6.4
Nalpha-benzoyl L-arginine ethyl ester
-
37°C, pH 7.6, mutant S55G
0.0031
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R372K, value below
0.012
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R372Q, value below
2.1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R205Q
3.7
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R205K
4
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A82V
4.9
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R609K
5.1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374Q
5.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484Q
5.5
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419Q
5.5
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant S55G
5.6
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R374K
5.9
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant A112G
6.2
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R484K
7.1
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123K
7.2
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156Q
7.8
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R156K
8.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R609Q
8.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639Q
8.7
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R639K
9
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R123Q
9.3
[histone H4]-L-Arg
-
37°C, pH 7.6, mutant R419K
10
[histone H4]-L-Arg
-
37°C, pH 7.6, wild-type
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A112G
-
K0.5 for Ca2+ higher than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
A82V
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
A82V/A112G
-
naturally occuring single-nucleotide polymorphisms and site-directed mutagenesis, the SNP-PADI4 mutant haplotype shows a higher risk of rheumatoid arthritis due to correlation with the RA gene, because the mutant shows increased activity, compared to the wild-type PADI4, which promotes the autoimmune disease and apoptosis, overview
C434A
small decrase in kcat/Km value
D273A/R544A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.35 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 13.5/sec, quaternary structure: dimer, Kd: 0.68 microM
D350A
no enzymic activity, catalytic residue
D369A
no enzymic activity, ligand for Ca2 coordination
D388A
81% of wild type activity, ligand for Ca4 coordination
D465A
residue involved in dimerization, about 30% of wild-type catalytic effciency
D473A
no enzymic activity, catalytic residue
D547A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.36 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 11.6/sec, quaternary structure: monomer/dimer, Kd: 6.4 microM
D547E
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.72 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 8.9/sec, quaternary structure: monomer/dimer, Kd: 11.2 microM
D547N
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.86 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 12.2/sec, quaternary structure: monomer/dimer, Kd: 4.9 microM
E281A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.45 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 12.1/sec, quaternary structure: dimer, Kd: 0.1 microM
E351A
33% of wild type activity, ligand for Ca2 coordination
E353A
no enzymic activity, ligand for Ca1 coordination
E354A
2000fold decrease in activity
E411A
no enzymic activity, ligand for Ca1 coordination
F285AV284A
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
F541A
residue at dimer interface, about 50% decrease in kcat/Km value
F576A
residue at dimer interface, about 50% decrease in kcat/Km value
G374R
-
the PAD3 mutant does not display PAD4-like kinetics with benzoylated arginine derivatives
H471A
no enzymic activity, catalytic residue
L279A
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
L279D
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
L279I
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
L6A
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
L6D
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
L6I
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
N373A
no enzymic activity, ligand for Ca2 coordination
N648A
37% of wild type activity, ligand for water-mediated Ca1 coordination
Q349A
no enzymic activity, ligand for Ca1 coordination
R123K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) comparable to wild-type
R123Q
-
K0.5 for Ca2+ higher than that obtained with the R123K mutant, but lower than wild-type, kcat/Km ([histone H4]-L-Arg) comparable to wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) comparable to wild-type
R156K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R156Q
-
K0.5 for Ca2+ comparable to wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R205K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R205Q
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R372A
almost complete loss of activity
R373A
2000fold decrease in activity
R374K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R374Q
-
K0.5 for Ca2+ comparable to wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R419K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) comparable to wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) comparable to wild-type
R419Q
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R441A
residue involved in dimerization, about 6% of wild-type catalytic effciency
R484K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R484Q
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R609K
-
K0.5 for Ca2+ comparable to wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R609Q
-
K0.5 for Ca2+ comparable to wild-type, kcat/Km ([histone H4]-L-Arg) lcomparable to wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R639A
about 30% decrease in kcat/Km value
R639K
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) comparable to wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R639Q
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) comparable to wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) lower than wild-type
R8A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.47 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 12.2/sec, quaternary structure: monomer/dimer, Kd: 9.3 microM
R8A/D547A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.4 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 10.7/sec, quaternary structure: monomer/dimer, Kd: 3.9 microM
R8E
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 1.06 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 7.3/sec, quaternary structure: monomer, Kd: 45.6 microM
R8E/D547E
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 2.77 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 3.3/sec, quaternary structure: monomer, Kd: 24 microM
R8H
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.47 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 13.3/sec, quaternary structure: dimer, Kd: 0.47 microM
R8K
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.5 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 10.8/sec, quaternary structure: monomer/dimer, Kd: 10.2 microM
R8L
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 1.36 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 5.3/sec, quaternary structure: monomer, Kd: 16.8 microM
R8Q
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.6 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 12.2/sec, quaternary structure: monomer/dimer, Kd: 15.7 microM
S55G
-
K0.5 for Ca2+ lower than wild-type, kcat/Km ([histone H4]-L-Arg) lower than wild-type, kcat/Km (Nalpha-benzoyl L-arginine ethyl ester) higher than wild-type
S55G/A112G
-
naturally occuring single-nucleotide polymorphisms and site-directed mutagenesis, the SNP-PADI4 mutant haplotype shows a higher risk of rheumatoid arthritis due to correlation with the RA gene, because the mutant shows increased activity, compared to the wild-type PADI4, which promotes the autoimmune disease and apoptosis, overview
S55G/A82V
-
naturally occuring single-nucleotide polymorphisms and site-directed mutagenesis, the SNP-PADI4 mutant haplotype shows reduced activity compared to the wild-type PADI4
S55G/A82V/A112G
-
naturally occuring single-nucleotide polymorphisms and site-directed mutagenesis, the SNP-PADI4 mutant haplotype shows a higher risk of rheumatoid arthritis due to correlation with the RA gene, because the mutant shows increased activity, compared to the wild-type PADI4, which promotes the autoimmune disease and apoptosis, overview
V283A
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V283D
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V283I
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V283T
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V284A
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V284D
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V284I
residue at dimer interface. Mutation decreases dimer formation and, consequently, enzyme activity
V469A
residue is critical for substrate binding at the active site. Mutation leads to a severe reduction in the catalytic activity
V469L
residue is critical for substrate binding at the active site. Mutation leads to a severe reduction in the catalytic activity
V469T
residue is critical for substrate binding at the active site. Mutation leads to a severe reduction in the catalytic activity
W347A
residue is critical for substrate binding at the active site. Mutation leads to a severe reduction in the catalytic activity
W347F
residue is critical for substrate binding at the active site. Mutation leads to a severe reduction in the catalytic activity
W373A
50fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
W548A
residue at dimer interface, complete loss of activity
W548F
residue at dimer interface, about 50% decrease in kcat/Km value
W548K
residue at dimer interface, about 50% decrease in kcat/Km value
Y237A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.36 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 13.9/sec, quaternary structure: dimer, Kd: 0.29 microM
Y237A/E281A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 0.38 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 13.2/sec, quaternary structure: dimer, Kd: 0.1 microM
Y435N
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 2.73 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 4/sec, quaternary structure: monomer, Kd: 33.8 microM
C645A
inactive mutant
C645A
no enzymic activity, catalytic residue
C645A
site-directed mutagemesis, inactive mutant, substrate-bound structure analysis
D123N
2.5fold decrease in activity
D123N
2.5fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D125A
2.75fold decrease in activity
D125A
2.75fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D166A
15fold decrease in activity
D166A
85fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D169A
2fold decrease in activity
D169A
2fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D177A
15fold decrease in activity
D177A
15fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D370A
145fold decrease in activity
D370A
220fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D374A
145fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
D374A
85fold decrease in activity
D389A
20fold decrease in activity
D389A
20fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
E352A
1250fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
E352A
220fold decrease in activity
E412A
200fold decrease in activity
E412A
3300fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
F221A/F222A
1.1fold increase in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
F221A/F222A
slight increase in activity, mutations do not significantly alter the calcium dependence of the enzyme
Q350A
2350fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
Q350A
3000fold decrease in activity
R347A
50fold decrease in activity
R347A
fold decrease in kcat/Km compared to wild-type value with N-alpha-benzoyl-L-arginine ethyl ester as substrate
R372K
complete loss of activity
R372K
-
830fold decreased in kcat/M with either substrate [histone H4]-L-Arg or Nalpha-benzoyl L-arginine ethyl ester
R372Q
almost complete loss of activity
R372Q
-
830fold decreased in kcat/M with either substrate [histone H4]-L-Arg or Nalpha-benzoyl L-arginine ethyl ester
Y435A
-
Km (Nalpha-benzoyl-L-arginine ethyl ester): 2.33 mM, kcat (Nalpha-benzoyl-L-arginine ethyl ester): 5.9/sec, quaternary structure: monomer, Kd: 30.3 microM
Y435A
residue involved in dimerization, about 4% of wild-type catalytic effciency
additional information
the promoter activity of MFZ1- and Sp1-binding site mutants is reduced, overview
additional information
-
the promoter activity of MFZ1- and Sp1-binding site mutants is reduced, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Pritzker, L.B.; Joshi, S.; Harauz, G.; Moscarello, M.A.
Deimination of myelin basic protein 3.5.3.15. Effect of methylation of MBP on its deimination by peptidylarginine deiminase
Biochemistry
39
5382-5388
2000
Bos taurus, Homo sapiens
brenda
Arita, K.; Hashimoto, H.; Shimizu, T.; Yamada, M.; Sato, M.
Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase V
Acta Crystallogr. Sect. D
59
2332-2333
2003
Homo sapiens
brenda
Arita, K.; Hashimoto, H.; Shimizu, T.; Nakashima, K.; Yamada, M.; Sato, M.
Structural basis for Ca2+-induced activation of human PAD4
Nat. Struct. Mol. Biol.
11
777-783
2004
Homo sapiens (Q9UM07), Homo sapiens
brenda
Zhang, J.; Dai, J.; Zhao, E.; Lin, Y.; Zeng, L.; Chen, J.; Zheng, H.; Wang, Y.; Li, X.; Ying, K.; Xie, Y.; Mao, Y.
cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type VI
Acta Biochim. Pol.
51
1051-1058
2004
Homo sapiens
brenda
Vossenaar, E.R.; Radstake, T.R.; van der Heijden, A.; van Mansum, M.A.; Dieteren, C.; de Rooij, D.J.; Barrera, P.; Zendman, A.J.; van Venrooij, W.J.
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages
Ann. Rheum. Dis.
63
373-381
2004
Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Sambandam, T.; Belousova, M.; Accaviti-Loper, M.A.; Blanquicett, C.; Guercello, V.; Raijmakers, R.; Nicholas, A.P.
Increased peptidylarginine deiminase type II in hypoxic astrocytes
Biochem. Biophys. Res. Commun.
325
1324-1329
2004
Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Nakayama-Hamada, M.; Suzuki, A.; Kubota, K.; Takazawa, T.; Ohsaka, M.; Kawaida, R.; Ono, M.; Kasuya, A.; Furukawa, H.; Yamada, R.; Yamamoto, K.
Comparison of enzymatic properties between hPADI2 and hPADI4
Biochem. Biophys. Res. Commun.
327
192-200
2005
Homo sapiens
brenda
Dong, S.; Kanno, T.; Yamaki, A.; Kojima, T.; Shiraiwa, M.; Kawada, A.; Mechin, M.C.; Chavanas, S.; Serre, G.; Simon, M.; Takahara, H.
NF-Y and Sp1/Sp3 are involved in the transcriptional regulation of the peptidylarginine deiminase type III gene (PADI3) in human keratinocytes
Biochem. J.
397
449-459
2006
Homo sapiens (Q9ULW8), Homo sapiens
brenda
Kearney, P.L.; Bhatia, M.; Jones, N.G.; Yuan, L.; Glascock, M.C.; Catchings, K.L.; Yamada, M.; Thompson, P.R.
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis
Biochemistry
44
10570-10582
2005
Homo sapiens (Q9UM07), Homo sapiens
brenda
Stone, E.M.; Schaller, T.H.; Bianchi, H.; Person, M.D.; Fast, W.
Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase
Biochemistry
44
13744-13752
2005
Homo sapiens (Q9UM07), Homo sapiens
brenda
Hagiwara, T.; Hidaka, Y.; Yamada, M.
Deimination of histone H2A and H4 at arginine 3 in HL-60 granulocytes
Biochemistry
44
5827-5834
2005
Homo sapiens
brenda
Cuthbert, G.L.; Daujat, S.; Snowden, A.W.; Erdjument-Bromage, H.; Hagiwara, T.; Yamada, M.; Schneider, R.; Gregory, P.D.; Tempst, P.; Bannister, A.J.; Kouzarides, T.
Histone deimination antagonizes arginine methylation
Cell
118
545-553
2004
Homo sapiens
brenda
Mechin, M.C.; Enji, M.; Nachat, R.; Chavanas, S.; Charveron, M.; Ishida-Yamamoto, A.; Serre, G.; Takahara, H.; Simon, M.
The peptidylarginine deiminases expressed in human epidermis differ in their substrate specificities and subcellular locations
Cell. Mol. Life Sci.
62
1984-1995
2005
Homo sapiens, Homo sapiens (Q9ULC6), Homo sapiens (Q9ULW8)
brenda
Hidaka, Y.; Hagiwara, T.; Yamada, M.
Methylation of the guanidino group of arginine residues prevents citrullination by peptidylarginine deiminase IV
FEBS Lett.
579
4088-4092
2005
Homo sapiens (Q9UM07)
brenda
Nachat, R.; Mechin, M.C.; Takahara, H.; Chavanas, S.; Charveron, M.; Serre, G.; Simon, M.
Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin
J. Invest. Dermatol.
124
384-393
2005
Homo sapiens (Q9ULC6), Homo sapiens (Q9ULW8), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Nachat, R.; Mechin, M.C.; Charveron, M.; Serre, G.; Constans, J.; Simon, M.
Peptidylarginine deiminase isoforms are differentially expressed in the anagen hair follicles and other human skin appendages
J. Invest. Dermatol.
125
34-41
2005
Homo sapiens, Homo sapiens (Q9ULW8), Homo sapiens (Q9Y2J8)
brenda
Ishigami, A.; Ohsawa, T.; Hiratsuka, M.; Taguchi, H.; Kobayashi, S.; Saito, Y.; Murayama, S.; Asaga, H.; Toda, T.; Kimura, N.; Maruyama, N.
Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease
J. Neurosci. Res.
80
120-128
2005
Homo sapiens
brenda
Chang, X.; Han, J.
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors
Mol. Carcinog.
45
183-196
2006
Homo sapiens (Q9UM07)
brenda
Arita, K.; Shimizu, T.; Hashimoto, H.; Hidaka, Y.; Yamada, M.; Sato, M.
Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4
Proc. Natl. Acad. Sci. USA
103
5291-5296
2006
Homo sapiens, Homo sapiens (Q9UM07)
brenda
Kubota, K.; Yoneyama-Takazawa, T.; Ichikawa, K.
Determination of sites citrullinated by peptidylarginine deiminase using 18O stable isotope labeling and mass spectrometry
Rapid Commun. Mass Spectrom.
19
683-688
2005
Homo sapiens
brenda
Chang, X.; Yamada, R.; Suzuki, A.; Sawada, T.; Yoshino, S.; Tokuhiro, S.; Yamamoto, K.
Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis
Rheumatology
44
40-50
2005
Homo sapiens
brenda
Harney, S.M.; Meisel, C.; Sims, A.M.; Woon, P.Y.; Wordsworth, B.P.; Brown, M.A.
Genetic and genomic studies of PADI4 in rheumatoid arthritis
Rheumatology
44
869-872
2005
Homo sapiens
brenda
Wang, Y.; Wysocka, J.; Sayegh, J.; Lee, Y.H.; Perlin, J.R.; Leonelli, L.; Sonbuchner, L.S.; McDonald, C.H.; Cook, R.G.; Dou, Y.; Roeder, R.G.; Clarke, S.; Stallcup, M.R.; Allis, C.D.; Coonrod, S.A.
Human PAD4 regulates histone arginine methylation levels via demethylimination
Science
306
279-283
2004
Homo sapiens
brenda
Zendman, A.J.; Raijmakers, R.; Nijenhuis, S.; Vossenaar, E.R.; Tillaart, M.; Chirivi, R.G.; Raats, J.M.; van Venrooij, W.J.; Drijfhout, J.W.; Pruijn, G.J.
ABAP: antibody-based assay for peptidylarginine deiminase activity
Anal. Biochem.
369
232-240
2007
Oryctolagus cuniculus, Mus musculus, Homo sapiens (Q9Y2J8), Homo sapiens, Mus musculus C57BL/6 / 129S
brenda
Hung, H.C.; Lin, C.Y.; Liao, Y.F.; Hsu, P.C.; Tsay, G.J.; Liu, G.Y.
The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells
Apoptosis
12
475-487
2007
Homo sapiens
brenda
Luo, Y.; Arita, K.; Bhatia, M.; Knuckley, B.; Lee, Y.H.; Stallcup, M.R.; Sato, M.; Thompson, P.R.
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization
Biochemistry
45
11727-11736
2006
Homo sapiens (Q9UM07)
brenda
Knuckley, B.; Luo, Y.; Thompson, P.R.
Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors
Bioorg. Med. Chem.
16
739-745
2008
Homo sapiens
brenda
Keilhoff, G.; Prell, T.; Langnaese, K.; Mawrin, C.; Simon, M.; Fansa, H.; Nicholas, A.P.
Expression pattern of peptidylarginine deiminase in rat and human Schwann cells
Dev. Neurobiol.
68
101-114
2007
Homo sapiens, Homo sapiens (Q9ULC6), Homo sapiens (Q9Y2J8), Rattus norvegicus
brenda
Algeciras, M.E.; Bhattacharya, S.K.
Targeting optic nerve citrullination in glaucoma: a role for protein-arginine deiminase 2 (PAD2) inhibitors
Drugs Future
32
999-1005
2007
Homo sapiens, Homo sapiens (Q6TGC4), Homo sapiens (Q9ULC6), Homo sapiens (Q9ULW8), Homo sapiens (Q9Y2J8), Rattus norvegicus, Rattus norvegicus (O88806), Rattus norvegicus (O88807), Rattus norvegicus (P20717), Rattus norvegicus (P70708)
-
brenda
Dong, S.; Ying, S.; Kojima, T.; Shiraiwa, M.; Kawada, A.; Mechin, M.C.; Adoue, V.; Chavanas, S.; Serre, G.; Simon, M.; Takahara, H.
Crucial roles of MZF1 and Sp1 in the transcriptional regulation of the peptidylarginine deiminase type I gene (PADI1) in human keratinocytes
J. Invest. Dermatol.
128
549-557
2008
Homo sapiens (Q9ULC6), Homo sapiens
brenda
Wood, D.D.; Ackerley, C.A.; Brand, B.; Zhang, L.; Raijmakers, R.; Mastronardi, F.G.; Moscarello, M.A.
Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities
Lab. Invest.
88
354-364
2008
Homo sapiens, Mus musculus (Q08642), Mus musculus (Q9Z183), Mus musculus CD-1 (Q08642), Mus musculus CD-1 (Q9Z183)
brenda
Makrygiannakis, D.; Hermansson, M.; Ulfgren, A.K.; Nicholas, A.P.; Zendman, A.J.; Eklund, A.; Grunewald, J.; Skold, C.M.; Klareskog, L.; Catrina, A.I.
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells
Ann. Rheum. Dis.
67
1488-1492
2008
Homo sapiens
brenda
Musse, A.A.; Polverini, E.; Raijmakers, R.; Harauz, G.
Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains
Biochem. Cell Biol.
86
437-447
2008
Homo sapiens
brenda
Stensland, M.E.; Pollmann, S.; Molberg, ?.; Sollid, L.M.; Fleckenstein, B.
Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4
Biol. Chem.
390
99-107
2009
Homo sapiens
brenda
Loos, T.; Mortier, A.; Gouwy, M.; Ronsse, I.; Put, W.; Lenaerts, J.P.; Van Damme, J.; Proost, P.
Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation
Blood
112
2648-2656
2008
Oryctolagus cuniculus, Homo sapiens
brenda
Musse, A.A.; Li, Z.; Ackerley, C.A.; Bienzle, D.; Lei, H.; Poma, R.; Harauz, G.; Moscarello, M.A.; Mastronardi, F.G.
Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system
Dis. Model. Mech.
1
229-240
2008
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8)
brenda
Ying, S.; Dong, S.; Kawada, A.; Kojima, T.; Chavanas, S.; Mechin, M.C.; Adoue, V.; Serre, G.; Simon, M.; Takahara, H.
Transcriptional regulation of peptidylarginine deiminase expression in human keratinocytes
J. Dermatol. Sci.
53
2-9
2009
Homo sapiens (Q6TGC4), Homo sapiens (Q9ULC6), Homo sapiens (Q9ULW8), Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Proost, P.; Loos, T.; Mortier, A.; Schutyser, E.; Gouwy, M.; Noppen, S.; Dillen, C.; Ronsse, I.; Conings, R.; Struyf, S.; Opdenakker, G.; Maudgal, P.C.; Van Damme, J.
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation
J. Exp. Med.
205
2085-2097
2008
Oryctolagus cuniculus, Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8)
brenda
Li, P.; Yao, H.; Zhang, Z.; Li, M.; Luo, Y.; Thompson, P.R.; Gilmour, D.S.; Wang, Y.
Regulation of p53 target gene expression by peptidylarginine deiminase 4
Mol. Cell. Biol.
28
4745-4758
2008
Homo sapiens (Q9UM07)
brenda
Abdeen, S.M.; Olusi, S.O.
Peptidyl arginine deiminase: A novel immunohistochemical marker for liver fibrosis in patients with chronic hepatitis
Acta Histochem.
112
592-603
2010
Homo sapiens
brenda
Knuckley, B.; Causey, C.P.; Jones, J.E.; Bhatia, M.; Dreyton, C.J.; Osborne, T.C.; Takahara, H.; Thompson, P.R.
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3
Biochemistry
49
4852-4863
2010
Homo sapiens
brenda
Knuckley, B.; Causey, C.P.; Pellechia, P.J.; Cook, P.F.; Thompson, P.R.
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation
ChemBioChem
11
161-165
2010
Homo sapiens
brenda
Jones, J.E.; Causey, C.P.; Knuckley, B.; Slack-Noyes, J.L.; Thompson, P.R.
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential
Curr. Opin. Drug Discov. Devel.
12
616-627
2009
Homo sapiens
brenda
Jang, B.; Jeon, Y.C.; Choi, J.K.; Park, M.; Kim, J.I.; Ishigami, A.; Maruyama, N.; Carp, R.I.; Kim, Y.S.; Choi, E.K.
Peptidylarginine deiminase modulates the physiological roles of enolase via citrullination: links between altered multifunction of enolase and neurodegenerative diseases
Biochem. J.
445
183-192
2012
Oryctolagus cuniculus, Homo sapiens
brenda
Slack, J.L.; Jones, L.E.; Bhatia, M.M.; Thompson, P.R.
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity
Biochemistry
50
3997-4010
2011
Homo sapiens
brenda
Rose, R.; Rose, M.; Ottmann, C.
Identification and structural characterization of two 14-3-3 binding sites in the human peptidylarginine deiminase type VI
J. Struct. Biol.
180
65-72
2012
Homo sapiens
brenda
Liu, Y.L.; Chiang, Y.H.; Liu, G.Y.; Hung, H.C.
Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4)
PLoS ONE
6
e21314
2011
Homo sapiens
brenda
Unno, M.; Kizawa, K.; Ishihara, M.; Takahara, H.
Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase type III
Acta Crystallogr. Sect. F
68
668-670
2012
Homo sapiens (Q9ULW8), Homo sapiens
brenda
Unno, M.; Kinjo, S.; Kizawa, K.; Takahara, H.
Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase type I
Acta Crystallogr. Sect. F
69
1357-1359
2013
Homo sapiens (Q9ULC6), Homo sapiens
brenda
Darrah, E.; Rosen, A.; Giles, J.; Andrade, F.
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: Novel insights into autoantigen selection in rheumatoid arthritis
Ann. Rheum. Dis.
71
92-98
2012
Homo sapiens (Q9ULW8), Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Dreyton, C.J.; Knuckley, B.; Jones, J.E.; Lewallen, D.M.; Thompson, P.R.
Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism
Biochemistry
53
4426-4433
2014
Homo sapiens (Q9Y2J8)
brenda
Assohou-Luty, C.; Raijmakers, R.; Benckhuijsen, W.E.; Stammen-Vogelzangs, J.; de Ru, A.; van Veelen, P.A.; Franken, K.L.; Drijfhout, J.W.; Pruijn, G.J.
The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities
Biochim. Biophys. Acta
1844
829-836
2014
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8)
brenda
Bozdag, M.; Dreker, T.; Henry, C.; Tosco, P.; Vallaro, M.; Fruttero, R.; Scozzafava, A.; Carta, F.; Supuran, C.T.
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors
Bioorg. Med. Chem. Lett.
23
715-719
2013
Homo sapiens (Q9UM07)
brenda
Jamali, H.; Khan, H.A.; Stringer, J.R.; Chowdhury, S.; Ellman, J.A.
Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method
J. Am. Chem. Soc.
137
3616-3621
2015
Homo sapiens (Q9ULW8)
brenda
Subramanian, V.; Knight, J.S.; Parelkar, S.; Anguish, L.; Coonrod, S.A.; Kaplan, M.J.; Thompson, P.R.
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors
J. Med. Chem.
58
1337-1344
2015
Homo sapiens (Q9ULC6), Homo sapiens (Q9ULW8), Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Slade, D.J.; Fang, P.; Dreyton, C.J.; Zhang, Y.; Fuhrmann, J.; Rempel, D.; Bax, B.D.; Coonrod, S.A.; Lewis, H.D.; Guo, M.; Gross, M.L.; Thompson, P.R.
Protein arginine deiminase 2 binds calcium in an ordered fashion implications for inhibitor design
ACS Chem. Biol.
10
1043-1053
2015
Homo sapiens (Q9Y2J8)
brenda
Jamali, H.; Khan, H.A.; Tjin, C.C.; Ellman, J.A.
Cellular activity of new small molecule protein arginine deiminase 3 (PAD3) inhibitors
ACS Med. Chem. Lett.
7
847-851
2016
Homo sapiens (Q9ULW8), Homo sapiens
brenda
Kunieda, K.; Kawaguchi, M.; Ieda, N.; Nakagawa, H.
Development of a highly sensitive fluorescence probe for peptidyl arginine deiminase (PAD) activity
Bioorg. Med. Chem. Lett.
29
923-928
2019
Homo sapiens (Q9UM07)
brenda
Teo, C.Y.; Tejo, B.A.; Leow, A.T.C.; Salleh, A.B.; Abdul Rahman, M.B.
Novel furan-containing peptide-based inhibitors of protein arginine deiminase type IV (PAD4)
Chem. Biol. Drug Des.
90
1134-1146
2017
Homo sapiens (Q9UM07)
brenda
Olson, J.S.; Lubner, J.M.; Meyer, D.J.; Grant, J.E.
An in silico analysis of primary and secondary structure specificity determinants for human peptidylarginine deiminase types 2 and 4
Comput. Biol. Chem.
70
107-115
2017
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Zhou, Y.; Mittereder, N.; Sims, G.
Perspective on protein arginine deiminase activity-bicarbonate is a pH-independent regulator of citrullination
Front. Immunol.
9
34
2018
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8)
brenda
Trabocchi, A.; Pala, N.; Krimmelbein, I.; Menchi, G.; Guarna, A.; Sechi, M.; Dreker, T.; Scozzafava, A.; Supuran, C.; Carta, F.
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors
J. Enzyme Inhib. Med. Chem.
30
466-471
2015
Homo sapiens (Q9UM07)
brenda
Damgaard, D.; Bjorn, M.E.; Jensen, P.O.; Nielsen, C.H.
Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase
J. Enzyme Inhib. Med. Chem.
32
1203-1208
2017
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Subramanian, V.; Knight, J.S.; Parelkar, S.; Anguish, L.; Coonrod, S.A.; Kaplan, M.J.; Thompson, P.R.
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors
J. Med. Chem.
58
1337-1344
2015
Homo sapiens (Q9UM07), Homo sapiens (Q9Y2J8), Homo sapiens
brenda
Saijo, S.; Nagai, A.; Kinjo, S.; Mashimo, R.; Akimoto, M.; Kizawa, K.; Yabe-Wada, T.; Shimizu, N.; Takahara, H.; Unno, M.
Monomeric form of peptidylarginine deiminase type I revealed by X-ray crystallography and small-angle X-ray scattering
J. Mol. Biol.
428
3058-3073
2016
Homo sapiens (Q9ULC6), Homo sapiens
brenda
Lee, C.; Lin, C.; Liu, Y.; Liu, G.; Liu, J.; Hung, H.
Molecular interplay between the dimer interface and the substrate-binding site of human peptidylarginine deiminase 4
Sci. Rep.
7
42662
2017
Homo sapiens (Q9UM07), Homo sapiens
brenda